	~~AMERICAN BIO MEDICA CORPORATION~~
	~~(Exact name of registrant as specified in its charter)~~

	New York		14-1702188
	(State or other jurisdiction of		~~(I.R.S. Employer~~
	incorporation or organization)		(I.R.S. Employer Identification No.)

	~~122 Smith Road, Kinderhook, New York~~		~~12106~~
	~~(Address of principal executive offices)~~		~~(Zip Code)~~

~~518-758-8158~~

122 Smith Road, Kinderhook, New York, 12106

~~(Registrant’s~~

(Address of principal executive offices) (Zip Code)

518-758-8158

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days xYes¨No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files)xYes¨No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, ~~or a~~ smaller reporting company, or an emerging growth company. See the definitions of “large accelerated ~~filer”,~~filer,” “accelerated filer” ~~and~~, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange ~~Act~~

Act. (Check one):

Large accelerated filer	¨☐	Accelerated filer	¨
			☐
Non-accelerated filer	¨ ☐ (Do not check if a smaller reporting company)	Smaller reporting company	x
			☒
		Emerging growth company	¨☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ~~Act~~Act. ☐¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)¨Yesx ☐ No

☑

Indicate the number of shares outstanding of each of the ~~issuer’s~~issuer's classes of common stock, as of the latest practicable date:

~~29,297,333~~

30,244,332 Common Shares as of ~~November~~August 14, ~~2017~~

2018

American Bio Medica Corporation

Index to Quarterly Report on Form 10-Q

For the quarter ended ~~September~~June 30, ~~2017~~

2018

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	22
Item 1.1A.	~~Legal Proceedings~~Risk Factors	20 22
~~Item 1A.~~	~~Risk Factors~~	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21 23
Item 3.	Defaults Upon Senior Securities	21 23
Item 4.	Mine Safety Disclosures	21 23
Item 5.	Other Information	21 23
Item 6.	Exhibits	21 23

Signatures		22

PART I –- FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

~~American Bio Medica Corporation~~

~~Condensed Balance Sheets~~

September 30, December 31,
2017 2016
(Unaudited)
ASSETS
Current assets
Cash and cash equivalents $ 150,000 $ 156,000
Accounts receivable, net of allowance for doubtful accounts of $51,000 at September 30, 2017 and $49,000 at December 31, 2016 521,000 556,000
Inventory, net of allowance of $453,000 at September 30, 2017 and $449,000 at December 31, 2016 1,462,000 1,582,000
Prepaid expenses and other current assets 49,000 92,000
Total current assets 2,182,000 2,386,000

Property, plant and equipment, net 810,000 824,000
Patents, net 107,000 93,000
Other assets 21,000 21,000
Deferred finance costs – line of credit, net 23,000 47,000
Total assets $ 3,143,000 $ 3,371,000

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable $ 306,000 $ 304,000
Accrued expenses and other current liabilities 287,000 276,000
Wages payable 257,000 299,000
Line of credit 580,000 639,000
Current portion of long-term debt 87,000 75,000
Total current liabilities 1,517,000 1,593,000

Long-term debt, net of current portion and deferred finance costs 748,000 753,000
Other long-term liabilities 22,000 0
Total liabilities 2,287,000 2,346,000

COMMITMENTS AND CONTINGENCIES

Stockholders’ equity:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at September 30, 2017 and December 31, 2016 0 0
Common stock; par value $.01 per share; 50,000,000 shares authorized; 29,297,333 issued and outstanding at September 30, 2017 and 28,842,788 issued and outstanding at December 31, 2016 293,000 288,000
Additional paid-in capital 21,115,000 21,037,000
Accumulated deficit (20,552,000 ) (20,300,000 )
Total stockholders’ equity 856,000 1,025,000
Total liabilities and stockholders’ equity $ 3,143,000 $ 3,371,000

American Bio Medica Corporation

Condensed Balance Sheets

June 30,

December 31,

2018

2017

ASSETS

(Unaudited)

Current assets

Cash and cash equivalents
$76,000
$36,000
Accounts receivable, net of allowance for doubtful accounts of $56,000 at June 30, 2018 and $52,000 at December 31, 2017
  512,000
  348,000
Inventory, net of allowance of $541,000 at June 30, 2018 and $500,000 at December 31, 2017
  1,261,000
  1,473,000
Prepaid expenses and other current assets
  33,000
  97,000
Total current assets
  1,882,000
  1,954,000



Property, plant and equipment, net
  754,000
  792,000
Patents, net
  119,000
  109,000
Other assets
  21,000
  21,000
Deferred finance costs – line of credit, net
  0
  15,000
Total assets
$2,776,000
$2,891,000



LIABILITIES AND STOCKHOLDERS’ EQUITY


Current liabilities


Accounts payable
$349,000
$374,000
Accrued expenses and other current liabilities
  358,000
  311,000
Wages payable
  252,000
  259,000
Line of credit
  596,000
  446,000
Current portion of long-term debt
  237,000
  87,000
Total current liabilities
  1,792,000
  1,477,000



Other liabilities/debt
  13,000
  19,000
Long-term debt, net of current portion and deferred finance costs
  733,000
  772,000
Total liabilities
  2,538,000
  2,268,000



COMMITMENTS AND CONTINGENCIES





Stockholders' equity:


Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at June 30, 2018 and December 31, 2017
  0
  0
Common stock; par value $.01 per share; 50,000,000 shares authorized; 29,966,554 issued and outstanding at June 30, 2018 and 29,782,770 issued and outstanding as of December 31, 2017
  300,000
  298,000
Additional paid-in capital
  21,196,000
  21,170,000
Accumulated deficit
  (21,258,000)
  (20,845,000)
Total stockholders’ equity
  238,000
  623,000
Total liabilities and stockholders’ equity
$2,776,000
$2,891,000

The accompanying notes are an integral part of the condensed financial statements

~~American Bio Medica Corporation~~

~~Condensed Statements of Operations~~

~~(Unaudited)~~

For The Nine Months Ended
September 30,
2017 2016

Net sales $ 3,975,000 $ 4,392,000

Cost of goods sold 2,279,000 2,441,000

Gross profit 1,696,000 1,951,000

Operating expenses:
Research and development 94,000 136,000
Selling and marketing 531,000 827,000
General and administrative 1,154,000 1,106,000
1,779,000 2,069,000

Operating loss (83,000 ) (118,000 )

Other income / (expense):
Interest expense (204,000 ) (210,000 )
Other income, net 34,000 200,000
(170,000 ) (10,000 )

Net loss before tax (253,000 ) (128,000 )

Income tax benefit / (expense) 1,000 (2,000 )

Net loss $ (252,000 ) $ (130,000 )

Basic and diluted loss per common share $ (0.01 ) $ (0.01 )

Weighted average number of shares outstanding – basic & diluted 29,129,168 27,056,216

American Bio Medica Corporation

Condensed Statements of Operations

(Unaudited)

For The Six Months Ended

June 30,

2018

2017

Net sales
$2,110,000
$2,621,000



Cost of goods sold
  1,301,000
  1,491,000



Gross profit
  809,000
  1,130,000



Operating expenses:


Research and development
  44,000
  68,000
Selling and marketing
  310,000
  372,000
General and administrative
  736,000
  778,000

  1,090,000
  1,218,000



Operating loss
  (281,000)
  (88,000)



Other income / (expense):


Interest expense
  (146,000)
  (134,000)
Other income, net
  15,000
  20,000
Interest income
  1,000
  0

  (130,000)
  (114,000)



Net loss before tax
  (411,000)
  (202,000)



Income tax expense
  (2,000)
  (1,000)



Net loss
$(413,000)
$(203,000)



Basic and diluted loss per common share
$(0.01)
$(0.01)



Weighted average number of shares outstanding – basic & diluted
  29,879,754
  29,043,692

The accompanying notes are an integral part of the condensed financial statements

~~American Bio Medica Corporation~~

~~Condensed Statements of Operations~~

~~(Unaudited)~~

For The Three Months Ended
September 30,
2017 2016

Net sales $ 1,354,000 $ 1,417,000

Cost of goods sold 788,000 806,000

Gross profit 566,000 611,000

Operating expenses:
Research and development 26,000 28,000
Selling and marketing 159,000 275,000
General and administrative 376,000 368,000
561,000 671,000

Operating income / (loss) 5,000 (60,000 )

Other income / (expense):
Interest expense (70,000 ) (71,000 )
Other income, net 14,000 44,000
(56,000 ) (27,000 )

Net loss before tax (51,000 ) (87,000 )

Income tax benefit / (expense) 2,000 (1,000 )

Net loss $ (49,000 ) $ (88,000 )

Basic and diluted loss per common share $ (0.00 ) $ (0.00 )

Weighted average number of shares outstanding – basic & diluted 29,297,333 27,284,308

American Bio Medica Corporation

Condensed Statements of Operations

(Unaudited)

For The Three Months Ended

June 30,

2018

2017

Net sales
$1,069,000
$1,306,000



Cost of goods sold
  632,000
  741,000



Gross profit
  437,000
  565,000



Operating expenses:


Research and development
  19,000
  22,000
Selling and marketing
  148,000
  176,000
General and administrative
  344,000
  388,000

  511,000
  586,000



Operating loss
  (74,000)
  (21,000)



Other income / (expense):


Interest expense
  (76,000)
  (69,000)
Other income, net
  4,000
  20,000
Interest income
  1,000
  0

  (71,000)
  (49,000)



Net loss before tax
  (145,000)
  (70,000)



Income tax expense
  (2,000)
  (1,000)



Net loss
$(147,000)
$(71,000)



Basic and diluted loss per common share
$(0.00)
$(0.00)



Weighted average number of shares outstanding – basic
  29,936,111
  29,242,388

The accompanying notes are an integral part of the condensed financial statements

~~American Bio Medica Corporation~~

~~Condensed Statements of Cash Flows~~

~~(Unaudited)~~

For The Nine Months Ended
September 30,
2017 2016
Cash flows from operating activities:
Net loss $ (252,000 ) $ (130,000 )
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization 64,000 69,000
Amortization of debt issuance costs 94,000 90,000
Provision for bad debts 2,000 0
Provision for slow moving and obsolete inventory 2,000 63,000
Share-based payment expense 33,000 49,000
Changes in:
Accounts receivable 32,000 (49,000 )
Inventory 116,000 127,000
Prepaid expenses and other current assets 96,000 21,000
Accounts payable 2,000 (38,000 )
Accrued expenses and other current liabilities 11,000 (6,000 )
Wages payable (42,000 ) (11,000 )
Net cash provided by operating activities 158,000 185,000

Cash flows from investing activities:
Patent application costs (20,000 ) (6,000 )
Purchase of property, plant & equipment (44,000 ) 0
Net cash used in investing activities (64,000 ) (6,000 )

Cash flows from financing activities:
Proceeds (payments) on debt financing (41,000 ) (75,000 )
Proceeds from lines of credit 4,729,000 4,609,000
Payments on lines of credit (4,788,000 ) (4,650,000 )
Net cash used in financing activities (100,000 ) (116,000 )

Net (decrease in) / increase in cash and cash equivalents (6,000 ) 63,000
Cash and cash equivalents - beginning of period 156,000 158,000

Cash and cash equivalents - end of period $ 150,000 $ 221,000

Supplemental disclosures of cash flow information
Cash paid during period for interest $ 110,000 $ 119,000
Cash paid / (received) during period for taxes $ (1,000 ) $ 2,000
Consulting expense prepaid with restricted stock $ 50,000 $ 49,000
Debt issuance cost paid with restricted stock $ 0 $ 96,000
Related party note payable paid with restricted stock $ 0 $ 154,000

American Bio Medica Corporation

Condensed Statements of Cash Flows

(Unaudited)

For The Six Months Ended

June 30

2018

2017

Cash flows from operating activities:

Net loss
$(413,000)
$(203,000)
  Adjustments to reconcile net loss to net cash provided by operating activities:


Depreciation and amortization
  42,000
  43,000
Amortization of debt issuance costs
  70,000
  63,000
Allowance for doubtful accounts
  4,000
  0
Provision for slow moving and obsolete inventory
  41,000
  19,000
Share-based payment expense
  7,000
  23,000
     Changes in:


Accounts receivable
  (168,000)
  74,000
Inventory
  171,000
  113,000
Prepaid expenses and other current assets
  64,000
  54,000
Accounts payable
  (25,000)
  (26,000)
Accrued expenses and other current liabilities
  48,000
  (13,000)
Wages payable
  (7,000)
  (31,000)
Net cash (used in) / provided by operating activities
  (166,000)
  116,000



Cash flows from investing activities:


Patent application costs
  (13,000)
  (13,000)
Purchase of property, plant and equipment
  0
  (38,000)
         Net cash used in investing activities
  (13,000)
  (51,000)



Cash flows from financing activities:


  Proceeds from / (payments on) debt financing
  69,000
  (38,000)
  Proceeds from lines of credit
  2,235,000
  2,835,000
  Payments on lines of credit
  (2,085,000)
  (2,880,000)
         Net cash provided by / (used in) financing activities
  219,000
  (83,000)



Net change in cash and cash equivalents
  40,000
  (18,000)
Cash and cash equivalents - beginning of period
  36,000
  156,000



Cash and cash equivalents - end of period
$76,000
$138,000



Supplemental disclosures of cash flow information


Non-cash transactions:


Consulting expense prepaid with restricted stock
$42,000
$50,000
Debt issuance cost paid with restricted stock
$18,000
$0
Director Fee paid with restricted stock
$3,000
$0
Cash paid during period for interest
$76,000
$71,000
Cash paid during period for taxes
$2,000
$1,000

The accompanying notes are an integral part of the condensed financial statements

Notes to condensed financial statements (unaudited)

~~September~~

June 30, ~~2017~~

2018

Note A –- Basis of Reporting

The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at ~~September~~June 30, ~~2017,~~2018, and the results of operations ~~for the three and nine month periods ended September 30, 2017 and September 30, 2016~~ and cash flows for the ~~nine~~three and six month periods ended ~~September~~June 30, ~~2017~~2018 and ~~September~~June 30, ~~2016.~~

2017.

Operating results for the ~~three and nine~~six months ended ~~September~~June 30, ~~2017~~2018 are not necessarily indicative of results that may be expected for the year ending December 31, ~~2017.~~2018. Amounts at December 31, ~~2016~~2017 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016.~~

2017.

During the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016.~~

2017.

The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates estimates, including those related to product returns, bad debts, inventories, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016,~~2017, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, ~~our~~the Company’s current cash balances, together with cash generated from future operations and amounts available under ~~our~~the Company’s credit facilities may not be sufficient to fund operations through ~~November 2018. On May 1, 2017, we extended our line of credit.~~August 2019. The ~~new expiration date of our~~Company’s current line of credit ismatures on June 29, 2020. The maximum availability on ~~our~~the Company’s line of credit remains to be $1,500,000. However, the amount available under ~~our~~the Company’s line of credit is based upon ~~our~~the Company’s accounts receivable and inventory. As of ~~September~~June 30, ~~2017,~~2018, based on ~~our~~the Company’s availability calculation, there were no additional amounts available under ~~our~~the Company’s line of credit because ~~we draw~~the Company draws any balance available on a daily basis.

As discussed in more detail in “Cash Flow, Outlook/Risk”, if sales levels decline further, wethe Company will have reduced availability on ~~our~~its line of credit due to decreased accounts receivable balances. In addition, wethe Company would expect ~~our~~its inventory levels to decrease if sales levels decline further, and this would also ~~will~~ result in reduced availability on the Company’s line of credit. In addition to this reduced availability, in June 2018, the Company’s line of credit was amended to reduce the maximum availability under the inventory component of its line of credit over the next 25 months. While this will not result in a dramatic impact to our availability today, it will ultimately remove availability related to our inventory under the line of credit. If availability under ~~our~~the Company’s line of credit is not sufficient to satisfy ~~our~~its working capital and capital expenditure requirements, wethe Company will be required to obtain additional credit facilities or sell additional equity securities, or delay capital expenditures. There is no assurance that such financing will be available or that wethe Company will be able to complete financing on satisfactory terms, if at all.

Recently Adopted Accounting Standards

~~We have disclosed~~

The Company adopted the ~~adoption of previously released~~following accounting standards set forth by the Financial Accounting Standards Board (“FASB”):

ASU 2014-09, “Revenue from Contracts with Customers”, issued in ~~earlier quarterly reports filed~~May 2014, provides guidance for revenue recognition. The core principle of ASU 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with the U.S. Securities and Exchange Commission (the “Commission”); these adoptions did not have an impact on our financial statement or results of operations. In the three months ended September 30, 2017, we determined thatcustomers. ASU ~~2017-07, “Compensation - Retirement Benefits” and ASU 2017-04 “Intangibles - Goodwill and Other (Topic 350)” (both previously disclosed in our Form 10-Q~~2014-09 provides for ~~the period ended June 30, 2017) did not apply~~two transition methods to the ~~Company. We did not adopt any~~ new ~~accounting standards in~~guidance: a retrospective approach and a modified retrospective approach. In August 2015, ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the ~~three months ended September 30, 2017.~~

~~Accounting Standards Issued; Not Yet Adopted~~

~~ASU 2017-11, “Earnings Per Share, Distinguishing Liabilities from Equity, Derivatives and Hedging”.~~ ~~ASU 2017-11~~Effective Date” was issued in July 2017. The amendments in ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature will no longer preclude equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) would not be accounted for as a ~~derivative liability at fair value as a result of~~revision to ASU 2014-09. ASU 2015-14 revised the ~~existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260~~effective date to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). ASU 2017-11 is effective for fiscal years, and interim periods within those ~~fiscal~~ years, beginning after December 15, ~~2018.~~2017. Subsequently, additional updates were issued related to this topic, ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20. Early adoption ~~is permitted. The Company is evaluating the impact~~ of ASU ~~2017-11.~~

~~ASU 2017-09, “Compensation – Stock Compensation (Topic 718)”.~~ ~~ASU 2017-09~~2014-09 was ~~issued in May 2017. The amendments in ASU 2017-09 provide guidance about which changes~~permitted but not prior to the terms or conditions of a share-based payment award require an entity to apply modification accounting. More specifically, that an entity should account for the effects of modification unless all the following are met: 1) the fair value, calculated or intrinsic value of the modified award is the same fair value, calculated or intrinsic value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original grant is modified. The current disclosure requirements in Topic 718 apply regardless of whether accounting modification is applied. ASU 2017-09 is effective for annual periods and interim periods within those annual periods beginning after December 15, ~~2017. Early~~2016 (i.e. the original adoption ~~is permitted.~~date per ASU No. 2014-09).

The Company's revenues result from the sale of goods and reflect the consideration to which the Company expects to be entitled. The Company ~~is evaluating the impact of~~records revenues based on a five-step model in accordance with ASU ~~2017-09.~~

~~ASU 2017-01, “Business Combinations (Topic 805)”.~~ ASU 2017-01 was issued in January 2017. The amendments in ASU 2017-01 clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for interim and annual periods beginning after December 15, 2017 and should be applied prospectively on or after the effective date.2014-09. The Company has defined purchase orders as contracts in accordance with ASU 2014-09. For its customer contracts, the Company’s performance obligations are identified; which is delivering goods at a determined transaction price, allocation of the contract transaction price with performance obligations (when applicable), and recognition of revenue when (or as) the performance obligation is transferred to the customer. Goods are transferred when the customer obtains control of the goods (which is upon shipment to the customer). The Company's revenues are recorded at a point in time from the sale of tangible products. Revenues are recognized when products are shipped.

The Company has elected the Modified Retrospective Method (the "Cumulate Effect Method") to comply with ASU 2014-09. The Cumulative Effect Method does not affect the amounts for the prior periods, but requires that the current period be reported in accordance with ASU 2014-09. ASU 2014-09 was adopted on January 1, 2018 which was the first day of the Company's 2018 fiscal year. There was no material impact on the Company’s financial position or results of operations.

Product returns, discounts and allowances are variable consideration and are recorded as a reduction of revenue in the ~~process of evaluating~~same period that the ~~impact of ASU 2017-01.~~

related sale is recorded. The Company has reviewed the overall sales transactions for variable consideration and has determined that these costs are not significant. The Company has not experienced any impairment losses, has no future performance obligations and does not capitalize costs to obtain or fulfill contracts.

Accounting Standards Issued; Not Yet Adopted

ASU 2016-02, “Leases”. ~~ASU 2016-02 was~~, issued in February 2016, ~~and it~~ requires a lessee to recognize a lease liability and a right-of-use asset on its balance sheet for all leases, including operating leases, with a term greater than 12 months. Lease classification will determine whether a lease is reported as a financing transaction in the income statement and statement of cash flows. ASU 2016-02 does not substantially change lessor accounting, but it does make certain changes related to leases for which collectability of the lease payments is uncertain or there are significant variable payments. Additionally, ASU 2016-02 makes several other targeted amendments including a) revising the definition of lease payments to include fixed payments by the lessee to cover lessor costs related to ownership of the underlying asset such as for property taxes or insurance; b) narrowing the definition of initial direct costs which an entity is permitted to capitalize to include only those incremental costs of a lease that would not have been incurred if the lease had not been obtained; c) requiring seller-lessees in a sale-leaseback transaction to recognize the entire gain from the sale of the underlying asset at the time of sale rather than over the leaseback term; and d) expanding disclosures to provide quantitative and qualitative information about lease transactions. ASU 2016-02 is effective for all annual and interim periods beginning January 1, 2019, and is required to be applied retrospectively to the earliest period presented at the date of initial application, with early adoption permitted. The Company is ~~currently~~ evaluating the impact of ~~adopting~~ ASU 2016-02.

ASU ~~2014-09, “Revenue~~2017-11, “Earnings Per Share, Distinguishing Liabilities from ~~Contracts with Customers”.~~ ~~ASU 2014-09 was~~Equity, Derivatives and Hedging”, issued in ~~May 2014~~July 2017, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature will no longer preclude equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) would not be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and ~~it provides~~as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for ~~revenue recognition. The core principle of~~contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). ASU ~~2014-09~~2017-11 is ~~that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange~~effective for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 provides for two transition methods to the new guidance: a retrospective approach and a modified retrospective approach. In August 2015, ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” was issued as a revision to ASU 2014-09. ASU 2015-14 revised the effective date to fiscal years, and interim periods within those fiscal years, beginning after December 15, ~~2017.~~2018. Early adoption is permitted. The Company is evaluating the impact of ASU 2017-11.

ASU 2018-07, “Compensation - Stock Compensation/Improvements to Nonemployee Share-Based Payment Accounting”, issued in June 2018, expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The requirements of Topic 718 must be applied to nonemployee awards except for certain exemptions specified in the amendment. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but ~~not prior to periods beginning after December 15, 2016 (i.e. the original~~no earlier than an entity’s adoption date ~~per ASU No. 2014-09).~~of Topic 606. The Company is ~~currently~~ evaluating ~~the transition methods and~~ the impact of ~~adopting this ASU.~~

ASU 2018-07.

There are no other accounting pronouncements issues during the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 that are expected to have or that could have a significant impact on our financial position or results of operations.

Reclassifications

Certain items have been reclassified from the prior year to conform to the current year presentation.

Note B – Inventory

Inventory is comprised of the following:

September 30, 2017 December 31, 2016

Raw Materials $ 1,053,000 $ 1,028,000
Work In Process 438,000 385,000
Finished Goods 424,000 618,000
Allowance for slow moving and obsolete inventory (453,000 ) (449,000 )
$ 1,462,000 $ 1,582,000

	June 30, 2018	December 31, 2017

Raw Materials	$1,031,000	$1,023,000
Work In Process	429,000	403,000
Finished Goods	342,000	547,000
Allowance for slow moving and obsolete inventory	(541,000)	(500,000)
	$1,261,000	$1,473,000

Note C – Net Loss Per Common Share

Basic net loss per common share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted net loss per common share includes the weighted average dilutive effect of stock options and warrants. Potential common shares outstanding as of ~~September~~June 30, ~~2017~~2018 and ~~2016:~~

September 30, 2017 September 30, 2016

Warrants 2,060,000 2,060,000
Options 2,147,000 2,182,000
4,207,000 4,242,000

2017:

	June 30, 2018	June 30, 2017

Warrants	2,000,000	2,060,000
Options	2,227,000	2,147,000
	4,227,000	4,207,000

The number of securities not included in the diluted net loss per share for the three and ~~nine~~six months ended ~~September~~June 30, 2018 was 4,227,000 as their effect would have been anti-dilutive due to the net loss in the three and six months ended June 30, 2018. The number of securities not included in the diluted net loss per share for the three and six months ended June 30, 2017 was 4,207,000 as their effect would have been anti-dilutive due to the net loss in ~~each period.~~

~~The number of securities not included in the diluted net loss per share for~~ the three and ~~nine~~six months ended ~~September~~June 30, ~~2016 was 4,242,000, as their effect would have been anti-dilutive due to the net loss in each period.~~

2017.

Note D – Litigation/Legal Matters

ABMC v. Premier Biotech, Inc., Todd Bailey, et al.

In February 2017, the Company filed a complaint in the Supreme Court of the State of New York in Columbia County against Premier Biotech Inc., Premier Biotech Labs, LLC and its principals, including its President Todd Bailey (“Bailey”), and Peckham Vocational Industries, Inc. (together the “Defendants”). ~~Mr.~~ Bailey formerly served as the Company’s Vice President of Sales and Marketing and as a sales consultant until December 23, 2016. The complaint seeks preliminary and permanent injunctions and a temporary restraining order against ~~Todd~~ Bailey (for his benefit or the benefit of another party or entity) related to the solicitation of Company customers as well as damages related to any profits and revenues that would result from actions taken by the Defendants related to Company customers.

In March 2017, the complaint was moved to the federal court in the Northern District of New York. In April 2017, the Defendants filed a motion to dismiss on the basis of jurisdiction, to which the Company responded on April 21, 2017. On

In July ~~10,~~ 2017, the Company was notified that it was not awarded a contract with a state agency for which it has held a contract in excess of 10 years. The contract in question is included in the February 2017 complaint. The Company believes that the Defendants actions related to this customer and a RFP that was issued by the state agency resulted in the loss of the contract award to the Company and the award of the contract to Peckham and Premier Biotech. This contract historically accounted for 10-15% of the Company’s annual revenue. The Company continued to hold a contract with the agency through September 30, 2017. The Company did protest the award of the contract to Peckham and Premier Biotech, and the state agency advised the Company on July 26, 2017 that they denied the Company’s protest of the award.

The Company amended its complaint against the Defendants to show actual damages caused by the Defendants and to show proprietary and confidential information (belonging to the Company) used by the Defendants in their response to the RFP. This confidential information belonging to the Company enabled the Defendants to comply with specifications of the RFP. The Defendants filed a response to the court opposing ~~our~~the Company’s supplemental motion and wethe Company filed ~~our~~ reply papers to the Defendants response on November 2, 2017.

In January 2018, the court ruled on the motion to dismiss (that was filed by the Defendants in April 2017). The court found that there was jurisdiction over Bailey only. In the Company’s opinion, this ruling does not diminish its standing in the case against Bailey, who again in the Company’s opinion, has always been the primary defendant. The court did not rule on the other motions before them. In February 2018, the Company filed a motion for reconsideration and for leave to serve a supplemental/amended complaint. The new filing asks for reconsideration in the jurisdiction ruling regarding Premier Biotech Inc. and addresses the Company’s intent to further supplement its complaint based on additional (subsequent) damage alleged by ABMC on the part of Bailey and Premier Biotech, Inc. The Company is still awaiting the court’s decision on the most recent filings. Given the stage of the litigation, management is not yet able to opine on the outcome of the case.

Todd Bailey v. ABMC

On October 20, 2017, the Company received notice that Bailey, its former Vice President of Sales & Marketing and sales consultant (and the same “Bailey” discussed above) filed a complaint against the Company in the State of Minnesota seeking deferred commissions of $164,000 that Bailey alleges is owed to him by the Company. On November 2, 2017, the Company filed a Notice of Removal in this action to move the matter from state to federal court. On November 9, 2017, the Company filed a motion to dismiss or, in the alternative to transfer venue and consolidate, the Bailey complaint with our litigation filed previously against Bailey and others.

In January 2018, the judge in the Minnesota case requested additional briefing on the impact of ruling in the New York case that determined there was personal jurisdiction over Bailey. The Company filed the requested briefing as requested by the court. Given the stage of the litigation, management is not yet able to opine on the outcome of the case. As of the date of this report, the ~~Company is awaiting the court’s rulings on the parties’ motions.~~

~~In addition, from time to time, the Company may be named~~action in legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such litigation cannot be predicted, if we are unsuccessful in defending any such litigation, the resulting financial losses could have an adverse effect on the financial position, results of operations and cash flows of the Company. We are aware of no significant litigation loss contingencies for which management believes it is both probable that a liabilityMinnesota has been ~~incurred and that~~stayed while the ~~amount of the loss can be reasonably estimated.~~

New York motions are decided.

Note E – Line of Credit and Debt

September 30, 2017 December 31, 2016
Loan and Security Agreement with Cherokee Financial, LLC: 5 year note at an annual interest rate of 8% plus a 1% annual oversight fee, interest only and oversight fee paid quarterly with first payment being made on May 15, 2015, annual principal reduction payment of $75,000 due each year beginning on February 15, 2016, with a final balloon payment being due on February 15, 2020. Loan is collateralized by a first security interest in building, land and property. $ 1,050,000 $ 1,125,000

Crestmark Line of Credit: Line of credit (with a current termination date of June 22, 2020) with interest payable at a variable rate based on WSJ Prime plus 2% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 2% if terminated in year 2 or after (and prior to natural expiration). Loan is collateralized by first security interest in receivables and inventory. 580,000 639,000

Crestmark Equipment Term Loan: 38 month equipment loan related to the purchase of manufacturing equipment, at an interest rate of WSJ Prime Rate plus 3%; or 7.25% as of the date of this report. 34,000 0
1,664,000 1,764,000
Less debt discount & issuance costs (Cherokee Financial, LLC Loan) (227,000 ) (297,000 )
Total debt, net 1,437,000 1,467,000

Current portion 667,000 714,000
Long-term portion, net of current portion $ 770,000 $ 753,000

June 30,
2018

December 31,
2017

Loan and Security Agreement with Cherokee Financial, LLC: 5 year note at an annual interest rate of 8% plus a 1% annual oversight fee, interest only and oversight fee paid quarterly with first payment being made on May 15, 2015, annual principal reduction payment of $75,000 due each year beginning on February 15, 2016, with a final balloon payment being due on February 15, 2020. Loan is collateralized by a first security interest in building, land and property.
$975,000
$1,050,000
Crestmark Line of Credit: 3 year line of credit maturing on June 22, 2020 with interest payable at a variable rate based on WSJ Prime plus 3% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 2% if terminated prior to natural expiration. Loan is collateralized by first security interest in receivables and inventory and the all-in interest rate as of the date of this report is 13.1%.
  596,000
  446,000
Crestmark Equipment Loan: 38 month equipment loan related to the purchase of manufacturing equipment, at an interest rate of WSJ Prime Rate plus 3%; or 8.00% as of the date of this report.
  25,000
  31,000
Term Loan with Cherokee Financial LLC: 1 year note at an annual interest rate of 12% paid quarterly in arrears with first interest payment being made on May 15, 2018 and a balloon payment being due on February 15, 2019.
  150,000
  0

  1,746,000
  1,527,000
Less debt discount & issuance costs (Cherokee Financial LLC loans)
  (167,000)
  (203,000)
Total debt, net
  1,579,000
  1,324,000



Current portion
  833,000
  533,000
Long-term portion, net of current portion
$746,000
$791,000

LOAN AND SECURITY AGREEMENT WITH CHEROKEE FINANCIAL, LLC

(“CHEROKEE”)

On March 26, 2015, the Company entered into a LSA with Cherokee Financial, LLC (the “Cherokee LSA”). The ~~purpose of the~~debt with Cherokee LSA was to refinance, at a better interest rate, the Company’s Series A Debentures and Cantone Asset Management Bridge Loan (both of which matured on February 1, 2015), as well as the Company’s Mortgage Consolidation Loan with First Niagara Bank (“First Niagara”). The loan is collateralized by a first security interest in real estate and machinery and equipment. Under the Cherokee LSA, the Company was provided the sum of $1,200,000 in the form of a 5-year Note at an annual interest rate of 8%. The Company is making interest only payments quarterly on the Cherokee ~~Note,~~LSA, with the first interest payment paid on May 15, 2015. The Company is also required to make an annual principal reduction payment of $75,000 on each anniversary of the date of the closing; with the first principal reduction payment being made on February 15, 2016 and the most recent principal reduction payment being made on February ~~16, 2017.~~15, 2018 with the proceeds received from a new term loan with Cherokee Financial, LLC (See “Term Loan with Cherokee” within this Note). A final balloon payment is due on March 26, 2020. In addition to the 8% interest, the Company pays Cherokee ~~Financial, LLC (“Cherokee”)~~ a 1% annual fee for oversight and administration of the loan. This oversight fee is paid in cash and is paid contemporaneously with the quarterly interest payments. The Company can pay off the Cherokee ~~Note~~loan at ~~anytime~~any time with no penalty; except that a 1% administration fee would be required to be paid to Cherokee to close out all participations.

The Company issued 1.8 million restricted shares of the Company’s common stock to Cherokee for payment of fees. In addition, because the loan was not repaid in full as of March 19, 2016, the Company issued another 600,000 restricted shares of common stock to Cherokee in March 2016.

As placement agent for the transaction, Cantone Research, Inc. (“CRI”) received a 5% cash fee on the $1.2 million, or $60,000, and 200,000 restricted shares of the Company’s common stock. In addition, because the loan was not repaid in full as of March 19, 2016, the Company issued another 196,000 restricted shares of common stock to CRI in March 2016.

The Company received net proceeds of $80,000 after $1,015,000 of debt payments, ~~$60,000~~and $105,000 in ~~placement agent fees, $19,000 in legal fees, $19,000 in~~other expenses ~~$3,000 in state filing fees~~ and ~~$4,000 in interest expense (for 8% interest on $511,000 in new participations received from February 24, 2015 through March 25, 2015).~~fees. With the adoption of ASU No. 2015-03 in the First Quarter of Fiscal 2016, these transaction costs (with the exception of the interest expense) are ~~now~~ being deducted from the balance on the Cherokee LSA and are being amortized over the term of the debt.

From these net proceeds, in April 2015, the Company also paid $15,000 in interest expense related to 15% interest on $689,000 in Series A Debentures and CAM Bridge Loan for the period of February 1, 2015 through March 25, 2015.

The Company recognized ~~$128,000~~$87,000 in interest expense related to the Cherokee LSA in the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 (of which ~~$70,000~~$47,000 is debt issuance cost amortization recorded as interest ~~expense as a result of the adoption of new accounting standards in the first quarter of 2016,~~expense) and, ~~$137,000~~$84,000 in interest expense related to the Cherokee LSA in the ~~nine~~six months ended ~~September~~June 30, ~~2016~~2017 (of which ~~$64,000 was~~$47,000 is debt issuance cost amortization recorded as interest ~~expense as a result of the adoption of new accounting standards in the first quarter of 2016)~~expense). The Company had $13,000 in accrued interest expense at June 30, 2018.

The Company recognized ~~$45,000~~$43,000 in interest expense related to the Cherokee LSA in the three months ended ~~September~~June 30, 2018 (of which $23,000 is debt issuance cost amortization recorded as interest expense), and $44,000 in interest expense related to the Cherokee LSA in the three months ended June 30, 2017 (of which $23,000 is debt issuance cost amortization recorded as interest expense as a result of the adoption of new accounting standards in the first quarter of 2016) and $47,000 in interest expense in the three months ended September 30, 2016 (of which $23,000 was debt issuance cost amortization recorded as interest expense as a result of the adoption of new accounting standards in the first quarter of 2016).

expense.

~~The Company had $11,000 in accrued interest expense at September 30, 2017, and $18,000 at December 31, 2016.~~

As of ~~September~~June 30, 2018, the balance on the Cherokee LSA was $975,000; however the discounted balance was $819,000. As of December 31, 2017, the balance on the Cherokee LSA iswas $1,050,000; however the discounted balance ~~is $823,000. As of December 31, 2016, the balance on the Cherokee LSA~~ was ~~$1,125,000; however the discounted balance, net of debt discount and debt issuance costs was $828,000.~~

$847,000.

LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”)

On June 29, 2015 (the “Closing Date”), the Company entered into a ~~three-year~~ Loan and Security Agreement (“LSA”) with Crestmark related to a ~~new Senior Lender, to refinance the Company’s Line~~revolving line of ~~Credit with Imperium Commercial Finance, LLC (“Imperium”~~credit (the “Crestmark LOC”). The Crestmark ~~Line of Credit~~LOC is used for working capital and general corporate ~~purposes. On May 1, 2017, the Company entered into term loan with Crestmark in the amount of $38,000 related to the purchase of manufacturing equipment (See “Equipment Loan with Crestmark”),~~purposes and in connection with this equipment loan, the Company executed an amendment to its LSA and Promissory Note with Crestmark. The amendments addressed the inclusion of the equipment loan into the Crestmark LSA and an extension of the Company’s line of credit with Crestmark. Apart from the extension of the LSA, no terms of the line of credit were changed in the amendment. The termination date of the Crestmark line of credit was changed fromexpires on June 22, ~~2018 to June 22, 2020 under the amendments.~~

~~Under the LSA,~~2020.

The Crestmark ~~is providing~~LOC provides the Company with a ~~Line~~revolving line of ~~Credit of~~credit up to $1,500,000 (“Maximum Amount”) with a minimum loan balance requirement of $500,000. The ~~Line of Credit~~Crestmark LOC is secured by a first security interest in the Company’s inventory, and receivables and security interest in all other assets of the Company (in accordance with permitted prior encumbrances).

The Maximum Amount is subject to an Advance Formula comprised of: 1) 90% of Eligible Accounts Receivables (excluding, receivables remaining unpaid for more than 90 days from the date of invoice and sales made to entities outside of the United States), and 2) up to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $350,000, or 100% of Eligible Accounts Receivable. However, as a result of an amendment executed on June 25, 2018, the amount available under the inventory component of the line of credit was changed to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $250,000 (“Inventory Sub-Cap Limit”), or 100% of ~~the~~ Eligible Accounts Receivable.

In addition, the Inventory Sub-Cap Limit will be permanently reduced by $10,000 per month commencing on July 1, 2018 and on the first day of the month thereafter until the Inventory Sub-Cap Limit is reduced to $0.

So long as any obligations are due to Crestmark, the Company must comply with a minimum Tangible Net Worth (“TNW”) Covenant. ~~Under~~As a result of an amendment executed on June 25, 2018, the ~~LSA,~~TNW covenant was reduced from $650,000 to $150,000 as ~~amended, the Company must maintain a TNW~~ of ~~at least $650,000.~~June 30, 2018. Additionally, if a quarterly net income is reported, the TNW covenant will increase by 50% of the reported net income. If a quarterly net loss is reported, the TNW covenant will remain the same as the prior quarter’s covenant amount. TNW is still defined as: Total Assets less Total Liabilities less the sum of (i) the aggregate amount of non-trade accounts receivables, including accounts receivables from affiliated or related persons, (ii) prepaid expenses, (iii) deposits, (iv) net lease hold improvements, (v) goodwill and (vi) any other asset that would be treated as an intangible asset under GAAP; plus Subordinated Debt. Subordinated Debt means any and all indebtedness presently or in the future incurred by the Company to any creditor of the Company entering into a written subordination agreement with Crestmark. The Company isdid not comply with the previous TNW covenant (of $650,000) for March 31, 2018, however, on June 25, 2018; the Company received a waiver from Crestmark with no further changes to the terms of the Crestmark LOC. The Company was also not in compliance with ~~this~~the new TNW covenant ~~at September~~as of June 30, ~~2017.~~

2018. The Company received a waiver from Crestmark for the June 30, 2018 non-compliance with no further changes to the terms of the Crestmark LOC.

If the Company terminates the LSA prior to June 22, 2020, an early exit fee of 2% of the Maximum Amount (plus any additional amounts owed to Crestmark at the time of termination) would be due.

In the event of a default of the LSA, which includes but is not limited to, failure of the Company to make any payment when due and non-compliance with the TNW covenant (that is not waived by Crestmark), Crestmark is permitted to charge an Extra Rate. The Extra Rate is the Company’s then current interest rate plus 12.75% per annum.

~~Under~~ As of the ~~LSA, interest~~date of this report, Crestmark has not elected to charge the Extra Rate even though the Company is not in compliance with the TNW covenant as of June 30, 2018.

Interest on the Crestmark ~~Line of Credit~~LOC is at a variable rate based on the ~~Wall Street Journal~~ Prime Rate plus 2%3% with a floor of 5.25%. As of ~~the date of this report,~~June 30, 2018, the interest only rate on the Crestmark ~~Line~~LOC was 8%. As of ~~Credit is 6.25%. In addition to the~~June 30, 2018, with all fees considered (the interest rate ~~on the Closing Date and on each one-year anniversary date thereafter, the Company will pay Crestmark a~~+ an Annual Loan Fee of ~~0.50%, or~~ $7,500 ~~and~~+ a ~~Monthly Maintenance Fee~~monthly maintenance fee of 0.30% of the actual average monthly ~~loan~~ balance from the prior ~~month will be paid to Crestmark. As of the date of this report,~~month), the interest rate ~~in effect is 10.93% (with all fees; including the weighted annual fee, which is charged~~ on the ~~closing date anniversary and is $7,500 regardless of our balance on the line of credit)~~Crestmark LOC was 13.1%.

In addition to the Loan Fee paid to Crestmark on the Closing Date, the Company had to pay a success fee (i.e. early termination fee) to Imperium in the amount of $50,000 on the Closing Date, and a Broker’s Fee of 5%, or $75,000, to Landmark Pegasus Inc. Prior to the Closing, the Company paid $12,000 in due diligence fees to Crestmark. The Company also incurred $3,000 of its own legal costs related to the Crestmark Line of Credit. With the exception of the early term fee ($50,000) paid to Imperium (which was fully expensed in the year ended December 31, 2015), these expenses are all being amortized over the initial term of the Crestmark Line of Credit, or three years.

The Company recognized ~~$24,000 of this expense~~$44,000 in the nine months ended September 30, 2017 and in the nine months ended September 30, 2016. The Company recognized $8,000 of this expense in the three months ended September 30, 2017 and in the three months ended September 30, 2016.

~~The Company recognized $76,000 of~~ interest expense related to the Crestmark ~~Line of Credit~~LOC in the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 (of which ~~$24,000~~$15,000 is debt issuance cost amortization recorded as interest ~~expense as a result~~expense) and $50,000 of ~~the adoption of new accounting standards) and $73,000 in~~ interest expense in the ~~nine~~six months ended ~~September~~June 30, ~~2016~~2017 (of which ~~$26,000~~$16,000 is debt issuance cost amortization recorded as interest expense).

The Company recognized ~~$25,000 of~~$23,000 in interest expense related to the Crestmark LOC in the three months ended ~~September~~June 30, ~~2017~~2018 (of which ~~$8,000~~$7,000 is debt issuance cost amortization recorded as interest expense) and $24,000 in interest expense in the three months ended ~~September~~June 30, ~~2016~~2017 (of which $8,000 is debt issuance cost amortization recorded as interest expense).

Given the nature of the administration of the Crestmark ~~Line of Credit,~~LOC, at ~~September~~June 30, ~~2017,~~2018, the Company had $0 in accrued interest expense related to the Crestmark ~~Line of Credit,~~LOC, and there is $0 in additional availability under the Crestmark ~~Line of Credit.~~

LOC.

As of ~~September~~June 30, 2018, the balance on the Crestmark LOC was $596,000, and as of December 31, 2017, the balance on the Crestmark ~~Line of Credit~~LOC was ~~$580,000, and as of December 31, 2016, the balance on the Crestmark Line of Credit was $639,000.~~

$446,000.

EQUIPMENT LOAN WITH CRESTMARK

On May 1, 2017, the Company entered into term loan with Crestmark in the amount of $38,000 related to the purchase of manufacturing equipment. The equipment loan is collateralized by a first security interest in a specific piece of manufacturing equipment. The Company executed an amendment to its LSA and Promissory Note with Crestmark. The amendments addressed the inclusion of the term loan into the LSA and an extension of the ~~Company’s line of credit with Crestmark.~~Crestmark LOC. No terms of the ~~line of credit~~Crestmark LOC were changed in the amendment. The interest rate on the term loan is the WSJ Prime Rate plus 3%; or ~~7.25%~~8% as of the date of this report. The ~~termination date of the Crestmark line of credit was changed from June 22, 2018 to June 22, 2020 under the amendments. The~~ balance on the equipment loan was ~~$34,000~~$25,000 as of ~~September~~June 30, 2018, and $31,000 as of December 31, 2017.

The Company incurred $1,000 in interest expense in the six months ended June 30, 2018 related to the Equipment Loan and less than $1,000 in interest expense in the six months ended June 30, 2017. The Company incurred less than $1,000 in interest expense in the three months ended June 30, 2018 related to the Equipment Loan and less than $1,000 in interest expense in the three months ended June 30, 2017.

TERM LOAN WITH CHEROKEE

On March 2, 2018, the Company entered into a one-year Loan Agreement made as of February 15, 2018 (the “Closing Date”) with Cherokee under which Cherokee provided the Company with $150,000 (the “Cherokee Term Loan”). The proceeds from the Cherokee Term Loan were used by the Company to pay a $75,000 principal reduction payment to Cherokee and $1,000 in legal fees incurred by Cherokee. Net proceeds (to be used for working capital and general business purposes) were $74,000.

The annual interest rate for the Cherokee Term Loan is 12% to be paid quarterly in arrears with the first interest payment being made on May 15, 2018. The Cherokee Term Loan is required to be paid in full on February 15, 2019 unless paid off earlier (with no penalty) at the Company’s sole discretion. In connection with the Cherokee Term Loan, the Company issued 150,000 restricted shares of common stock to Cherokee on March 8, 2018.

In the event of default, this includes, but is not limited to, the Company’s inability to make any payments due under the Cherokee Term Loan, Cherokee has the right to increase the interest rate on the Cherokee Term Loan to 18% and the Company would be required to issue and additional 150,000 restricted shares of common stock to Cherokee.

The Company recognized $14,000 in interest expense related to the Cherokee Term Loan in the six months ended June 30, 2018 (of which $8,000 was debt issuance costs recorded as interest expense) and $0 in interest expense in the six months ended June 30, 2017 (as the facility was not yet in place). The Company recognized $9,000 in interest expense related to the Cherokee Term Loan in the three months ended June 30, 2018 (of which $5,000 was debt issuance costs recorded as interest expense) and $0 in interest expense in the three months ended June 30, 2017 (as the facility was not yet in place).

As of June 30, 2018, the balance on the Cherokee Term Loan is $150,000 however the discounted balance is $142,000. As of December 31, 2017, the balance on the Cherokee Term loan was $0 (as the facility was not in place at December 31, 2017).

NOTE F – Stock Options and Warrants

The Company currently has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by our Board of Directors and approved by our shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares.

During the three months ended ~~September~~June 30, ~~2017 and September 30, 2016,~~2018, the Company issued 0options to purchase 20,000 shares of stock ~~options.~~

to each of its non-employee board members as an annual stock option grant (for a total of 80,000 options) under the 2001 Plan. During the three months ended June 30, 2017, the Company issued options to purchase 20,000 shares of stock to each of its two non-employee board members as an annual stock option grant (for a total of 40,000 options) under the 2001 Plan.

Stock option activity for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~September~~June 30, ~~2016~~2017 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand):

Nine months ended September 30, 2017 Nine months ended September 30, 2016

Shares
Weighted
Average
Exercise
Price
Aggregate
Intrinsic
Value as of
September 30,
2017

Shares

Weighted
Average
Exercise
Price

Aggregate
Intrinsic
Value as of
September 30,
2016

Options outstanding at beginning of period 2,107,000 $ 0.13 1,435,000 $ 0.13
Granted 40,000 $ 0.13 830,000 $ 0.11
Exercised 0 NA 0 NA
Cancelled/expired 0 NA (83,000 ) $ 0.19
Options outstanding at end of period 2,147,000 $ 0.13 $ 15,000 2,182,000 0.13 $ 30,000
Options exercisable at end of period 1,647,000 $ 0.13 1,184,000 $ 0.14

	Six months ended June 30, 2018			Six months ended June 30, 2017
	Shares	Weighted Average Exercise Price	Aggregate Intrinsic Value as of June 30, 2018	Shares	Weighted Average Exercise Price	Aggregate Intrinsic Value as of June 30, 2017
Options outstanding at beginning of period	2,147,000	$0.13		2,107,000	$0.13
Granted	80,000	$0.10		40,000	$0.13
Exercised	0	NA		0	NA
Cancelled/expired	0	NA		0	NA
Options outstanding at end of period	2,227,000	$0.13	$5,000	2,147,000	$0.13	$15,000
Options exercisable at end of period	2,147,000	$0.13		1,647,000	$0.13

The Company recognized $7,000 in share based payment expense in the six months ended June 30, 2018 and $23,000 in share based payment expense in the six months ended June 30, 2017. The Company recognized $3,000 in share based payment expense in the three months ended June 30, 2018 and $11,000 in share based payment expense in the three months ended June 30, 2017. At June 30, 2018 there was approximately $6,000 of total unrecognized share based payment expense related to stock options. This cost is expected to be recognized over 11 months.

The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~September~~June 30, ~~2016:~~

Nine months ended
2017 2016
Volatility 81 % 62% - 66 %
Expected term (years) 10 years 10 years
Risk-free interest rate 2.16 % 1.57% - 1.94 %
Dividend yield 0 % 0 %

The Company recognized $33,000 in share based payment expense in the nine months ended September 30, 2017 and $49,000 in share based payment expense in the nine months ended September 30, 2016. The Company recognized $10,000 in share based payment expense in the three months ended September 30, 2017 and $13,000 in share based payment expense in the three months ended September 30, 2016. As of September 30, 2017, there was approximately $16,000 of total unrecognized compensation cost related to non-vested stock options, which vest over time. The cost is expected to be recognized over a period ranging from 3-8 months.

2017:

	Six months ended
	2018	2017
Volatility	79%	81%
Expected term (years)	10 years	10 years
Risk-free interest rate	2.90%	2.16%
Dividend yield	0%	0%

Warrants

Warrant activity for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~September~~the six months ended June 30, ~~2016~~2017 is summarized as follows:

Nine months ended September 30, 2017 Nine months ended September 30, 2016

Shares
Weighted
Average
Exercise
Price
Aggregate
Intrinsic Value
as of
September 30,
2017

Shares
Weighted
Average
Exercise
Price Aggregate
Intrinsic Value
as of
September 30,
2016
Warrants outstanding at beginning of period 2,060,000 $ 0.18 2,385,000 $ 0.17
Granted 0 NA 0 NA
Exercised 0 NA 0 NA
Cancelled/expired 0 NA (325,000 ) $ 0.14
Warrants outstanding at end of period 2,060,000 $ 0.18 $ 0 2,060,000 $ 0.18 $ 0
Warrants exercisable at end of period 2,060,000 $ 0.18 2,060,000 $ 0.18

	Six months ended June 30, 2018			Six months ended June 30, 2017
	Shares	Weighted Average Exercise Price	Aggregate Intrinsic Value as of June 30, 2018	Shares	Weighted Average Exercise Price	Aggregate Intrinsic Value as of June 30, 2017
Warrants outstanding at beginning of period	2,060,000	$0.18		2,060,000	$0.18
Granted	0	NA		0	NA
Exercised	0	NA		0	NA
Cancelled/expired	60,000	$0.18		0	NA
Warrants outstanding at end of period	2,000,000	$0.18	None	2,060,000	$0.18	None
Warrants exercisable at end of period	2,000,000	$0.18		2,060,000	$0.18

In the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~September~~June 30, ~~2016,~~2017, the Company recognized $0 in debt issuance and deferred finance costs related to the issuance of the above warrants outstanding. In the three months ended ~~September~~June 30, ~~2017~~2018 and ~~September~~June 30, ~~2016,~~2017, the Company recognized $0 in debt issuance and deferred finance costs related to the issuance of the above warrants. As of ~~September~~June 30, ~~2017,~~2018, there was $0 of total unrecognized expense.

NOTE G –- SUBSEQUENT EVENT

~~On October 20, 2017,~~

The Company entered into an addendum to its Financial Advisory Agreement with Landmark Pegasus, Inc. (‘Landmark”) on August 1, 2018. Under the Financial Advisory Agreement, Landmark provides certain financial advisory services to the Company ~~received notice that Todd Bailey (“Bailey”), its former Vice President~~from July 1, 2018 through December 31, 2018. As consideration for these services, the Company will pay Landmark a retainer fee consisting of ~~Sales & Marketing~~277,778 restricted shares of common stock and ~~sales consultant~~the Company will pay Landmark a “success fee” for the consummation of each and any transaction closing during the term of the Financial Advisory Agreement and for 24 months thereafter, inclusive of a sale or merger, between the Company and any party first introduced to the Company by Landmark, or for any other transaction not originated by Landmark but for which Landmark provides substantial support in completing during the term of the Agreement. For certain transactions, the success fee will be paid part upon consummation of a transaction and part paid over a term of not more than five years; all other transactions would be paid upon consummation of the transaction.

As a result of the retainer fees being paid in restricted shares and the resulting percentage of common share ownership, Landmark filed a ~~complaint against~~Schedule 13G in October 2016 related to its ownership of the Company’s common stock and its principal John Moroney has continued to file required Section 16(a) forms. Apart from their status as a shareholder and with respect to the Agreement, there is no material relationship between the Company in the State of Minnesota seeking deferred commissions of $164,000 that Bailey alleges is owed to him by the Company. Bailey is one of the defendants in the litigation discussed previously in Note D. On November 2, 2017, we filed a Notice of Removal in this action to move the matter from state to federal court. On November 9, 2017, we filed a motion to dismiss or, in the alternative to transfer venue and ~~consolidate, the Bailey complaint with our litigation filed previously against Bailey and others (see Note D).~~

Landmark.

Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

General

The following discussion and analysis provides information, which we believe is relevant to an assessment and understanding of our financial condition and results of operations. The discussion should be read in conjunction with the Interim Condensed Financial Statements contained herein and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. Certain statements contained in this Quarterly Report on Form 10-Q, including, without limitation, statements containing the words “believes”, “anticipates”, “estimates”, “expects”, “intends”, “projects”, and words of similar import, are forward-looking as that term is defined by the Private Securities Litigation Reform Act of 1995 (“1995 Act”), and in releases issued by the United State Securities and Exchange Commission (the “Commission”). These statements are being made pursuant to the provisions of the 1995 Act and with the intention of obtaining the benefits of the “Safe Harbor” provisions of the 1995 Act. We caution that any forward-looking statements made herein are not guarantees of future performance and that actual results may differ materially from those in such forward-looking statements as a result of various factors, including, but not limited to, any risks detailed herein, in our “Risk Factors” section of our Form 10-K for the year ended December 31, ~~2016,~~2017, in our most recent reports on Form 10-Q and Form 8-K and from time to time in our other filings with the Commission, and any amendments thereto. Any forward-looking statement speaks only as of the date on which such statement is made, and we are not undertaking any obligation to publicly update any forward-looking statements. Readers should not place undue reliance on these forward-looking statements.

Overview/Plan of Operations

~~Our ability to maintain and/or increase sales continues to be~~

Sales in the six months ended June 30, 2018 were negatively impacted by ~~a very cost-competitive market currently dominated by products made outside~~the loss of an account in the fourth quarter of the ~~United States. Evidenced by~~year ended December 31, 2017 and the ~~fact that sales~~expiration of another government account in the ~~nine~~three months ended ~~September~~June 30, 2018. The account lost in 2017 ~~decreased again when compared to~~is a subject of the ~~same period last year. In addition, our sales have been impacted by actions taken by~~litigation we initiated against a former Vice President, Sales & Marketing/Sales ~~Consultant. We have initiated litigation against this former employee/consultant related to these actions (see~~Consultant (See Note D – Litigation/Legal Matters).

During the nine months ended September 30, 2017, we recorded an operating loss of $83,000. This compares to an operating loss of $118,000 in the same period last year. Decreased operating expenses were the primary cause Along with these losses, products manufactured outside of the improvement in operating loss (relative to sales). Net loss in the nine months ended September 30, 2017 was $252,000, compared to a net loss of $130,000 in the same period last year. This is primarily due to other income of $200,000 (of which $150,000 was related to a tech transfer with a contract manufacturing customer) in the nine months ended September 30, 2016 that did not reoccur in the nine months ended September 30, 2017.

We had cash provided by operating activities of $158,000 in the nine months ended September 30, 2017. This compares to cash provided by operating activities of $185,000 in the nine months ended September 30, 2016.

~~We continuously examine all expenses in efforts to achieve profitability (when/if sales levels improve) or to minimize losses going forward (if sales~~United States continue to ~~decline). Over~~dominate our markets; especially those markets where cost is the course of the last two fiscal years (Fiscal 2016 and Fiscal 2015), we refinanced substantially all of our existing debt at lower interest rates, manufactured our products in a partially consolidated operating environment, and maintained a salary and commission deferral program; all as part of our efforts to decrease expenses and improve cash flow.

The salary and commission deferral program previously referenced continued throughout the nine months ended September 30, 2017. The deferral program currently consists of a 20% salary deferral for our executive officer and our non-executive VP Operations (and previously included the former Vice President Sales & Marketing/Sales Consultant referred to earlier in this report; until his termination in December 2016). As of September 30, 2017, we had total deferred compensation owed of $253,000. Over the course of the program, we repaid portions of the deferred compensation (with $29,000 in payments in the nine months ended September 30, 2017 and $70,000 in payments in the nine months ended September 30, 2016.). As cash flow from operations allows, we intend to continue to make paybacks, however the deferral program is continuing and we expect it will continue for up to another 12 months.

driving factor.

We continue to believe that new products and our ability to sell those products in new markets will be a future growth driver. In August 2017, the U.S. Food and Drug Administration granted over-the-counter marketing clearance for our Rapid TOX Cup II (an all-inclusive, urine based drug testing cup). We are hopeful that this marketing clearance will enable us to further penetrate clinical markets as to increase our business with our laboratory alliance.

Although our primary markets continue to be extremely price-competitive, this marketing clearance should enable us to garner new sales in clinical markets (such as pain management and drug treatment) because although price is always a factor, quality and accuracy are equally important in these clinical markets.

New assays and product platform developments are also in our future research and development plans. We remain focused on selling our point of collection drugs of abuse tests, and growing our business through direct sales and select distributors.

~~Over the course of the last 12 months, we~~ have ~~reorganized and restructured our sales and marketing department. In addition, we~~ brought on new products and service offerings to diversify our revenue stream through third party relationships. These new products and services include products for the detection of alcohol, alternative sample options for drug testing (such as lab based oral fluid testing and hair testing) as well as toxicology management services. ~~In addition, we~~We are also now offering customers lower-cost alternatives for onsite drug testing. While we are not yet seeing significant revenue from these additions; we have continued to see a trend of increasing sales of the lower cost product alternative.

We are focusing our efforts on 1) further penetration of the clinical markets with new products, 2) drug testing with oral fluid in the workplace and 3) contract manufacturing. To further penetrate the clinical markets we retained a Director of Clinical Sales in January 2018 to spearhead our efforts in the rehabilitation/drug treatment, pain management and other clinical markets. We are hopeful that our OTC marketing clearance for our Rapid TOX Cup® II product line, lower cost product alternatives and the renewed focus on clinical markets will enable us to increase sales in this area. In addition, we are currently working with our laboratory alliance in efforts to increase sales under our current contract. A change in the regulatory environment (due to certain exemptions set forth by the U.S. Food and Drug Administration related to workplace and insurance drug testing) has resulted in new efforts to re-enter the workplace market with oral fluid drug testing options. And finally, we are ~~reviewing our~~currently discussing a number of contract manufacturing ~~operations~~opportunities with other entities; one of which is expected to generate sales starting in the 3rd or 4th quarter of 2018.

Operating expenses continued to decline when comparing the six and three months ended June 30, 2018 with the six and three months ended June 30, 2017. This is a result of our continued efforts to ~~capitalize on offerings~~ensure that expenses are in ~~that area. We have not derived any significant revenue from these new additions; however,~~line with revenue. In the ~~majority~~six months ended June 30, 2018, we consolidated job responsibilities in certain areas of the ~~relationships were only finalized in March/April 2017.~~

~~In September 2016, our contract manufacturing sales began to decrease on an annual basis due to a manufacturing shift with one of our contract customers. More specifically,~~Company as a result of employee retirement and other departures; this consolidation enabled us to implement personnel reductions. We also continued to maintain a ~~tech transfer with~~salary deferral program for our sole executive officer and another member of senior management throughout the ~~customer, they are now their own primary supplier with~~six months ended June 30, 2018. The salary deferral program consists of a 20% salary deferral for our Chief Executive Officer/Principal Financial Officer Melissa Waterhouse and our non-executive VP Operations. As of June 30, 2018, we had total deferred compensation owed of $296,000. As cash flow from operations allows, we intend to repay portions of the ~~Company moving into a position of back up or secondary supplier. Although contract manufacturing is~~deferred compensation, however we did not considered a material portion of our net sales, given this expected change, we are making efforts to identify and secure new contract work and possible diversification alternatives. In connection with the tech transfer, we received a $300,000 tech transfer fee from this customer. We recognized $150,000 related to this tech transfer fee as other incomemake any payments on deferred compensation in the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~

2018. We did make $16,000 in payments in the six months ended June 30, 2017. We expect the salary deferral program will continue for up to another 12 months.

Our continued existence is dependent upon several factors, including our ability to: 1) raise revenue levels even though we have ~~suffered~~lost significant accounts and the ~~loss~~market continues to be infiltrated by product manufactured outside of ~~a material contract that will impact sales starting October 1, 2017,~~the United States, 2) control operational costs to generate positive cash flows, 3) maintain our current credit facilities or refinance our current credit facilities if necessary, and 4) if needed, our ability to obtain working capital by selling additional shares of our common stock.

Results of operations for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~

2018,

compared to the ~~nine~~six months ended ~~September~~June 30, ~~2016~~

2017

NET SALES:Net sales for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 decreased 9.5% when compared to net sales in the nine months ended September 30, 2016. The decrease in sales is a result of the anticipated decrease in contract manufacturing sales in the nine months ended September 30, 2017$511,000, or 19.5%, when compared to the ~~nine~~six months ended ~~September~~June 30, ~~2016. More specifically, contract manufacturing~~2017. The majority of the sales declined by approximately $222,000 (of which $197,000 was to the customer involved with the tech transfer). The remaining $195,000 in decreased sales resulted primarily from a decrease in government sales (most of whichdecline is due to ~~the loss of an~~$456,000 in product sales to a government account lost in the ~~fourth quarter~~latter part of the year ended December 31, ~~2016)~~2017. The loss of this account is due to actions we have alleged were taken by a former Vice President Sales & Marketing/Sales Consultant (Todd Bailey) and, are the subject of ongoing litigation. There was an additional $51,000 in lost government product sales due to the expiration of a contract with another government entity. Contract manufacturing sales also contributed $18,000 to the sales loss with the anticipated expiration of one of our contract manufacturing agreements in early 2018). ~~These declines were partially offset by an increase~~In the six months ended June 30, 2018, we did see some improvement in ~~national accounts~~other areas of government and international sales, ~~to Latin~~ and ~~South America.~~

we also saw increased sales of our lower cost product alternative. These improvements minimally offset the declines.

GROSS PROFIT:Gross profit ~~in the nine months ended September 30, 2017~~ decreased to ~~42.7% of net sales compared to 44.2%~~38.3% of net sales in the ~~nine~~six months ended ~~September~~June 30, ~~2016. While we are still maintaining manufacturing efficiencies, there were certain periods within~~2018, from 43.1% of net sales in the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2017. This decrease in gross profit stems primarily from the fact that ~~we produced less~~decreased sales resulted in a decrease in the number of testing strips ~~due~~made in the six months ended June 30, 2018, when compared to the six months ended June 30, 2017. The majority of our labor and overhead costs are fixed. When revenues decline, fewer testing strips are produced; this results in a manufacturing inefficiency (i.e. less fixed overhead cost absorption and a higher amount being expensed through cost of goods). In addition, the low product ~~sales mix.~~

~~OPERATING EXPENSES:~~prices from foreign manufacturers have required us to decrease pricing of our own products to be more competitive. We have taken actions to adjust our production schedules to mitigate future inefficiencies

Operating expenses decreased ~~14.0%~~$145,000, or 11.9%, in the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 compared to the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2017. Expenses in ~~research and development and selling and marketing decreased while general and administrative expense increased.~~all operational areas of the Company decreased. More specifically:

Research and development (“R&D”)

R&D expense decreased ~~30.9%~~$24,000, or 35.3%, when comparing the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 with the ~~same period last year.~~six months ended June 30, 2017. Decreased FDA compliance costs ~~associated~~(associated with the timing of actions taken related to our FDA marketing clearance application) were the primary reason for ~~Rapid TOX Cup II~~the decline in expenses. All other expense remained relatively consistent. In the six months ended June 30, 2018 our R&D department primarily focused their efforts on the evaluation and development of potential contract manufacturing opportunities.

Selling and marketing

Selling and marketing expense in the six months ended June 30, 2018 decreased $62,000, or 16.7% when compared to the six months ended June 30, 2017. Marketing salaries and benefits decreased due to transitioning from an employee based approach to internet marketing to the use of a consulting firm; this expense savings was only nominally offset by an increase in marketing consulting expense. There were also reductions in postage and freight expenses, as well as reduced telephone expense (due to changing telephone vendors). These reductions were partially offset by increased consulting fees (as discussed previously) and increased costs associated with promotional expense and trade show attendance. In the six months ended June 30, 2018, we promoted additional products (through relationships with third parties) for the detection of alcohol, alternative sample options for drug testing (such as lab based oral fluid testing and hair testing) as well as toxicology management services and lower-cost alternatives for onsite drug testing. The addition of these offerings did not result in increased selling and marketing expenses. In the six months ended June 30, 2018, we refocused our efforts on further penetration of the clinical markets, took efforts to re-enter the workplace market with oral fluid drug testing options and increase our contract manufacturing business.

General and administrative (“G&A”)

G&A expense decreased $42,000, or 5.4%, in the six months ended June 30, 2018 when compared to G&A expense in the six months ended June 30, 2017. Decreases in SEC report fees (due to a change in vendor), Quality Assurance (“QA”) salaries (due to retirement of an employee), QA supplies, purchasing salaries, broker fees (due to timing of financing activities), legal fees (due to timing of actions in the ABMC vs. Bailey et al litigation), patents and licenses (due to less patent activity) and share based a payment expense (due to less stock option amortization in 2018) were offset by certain increases. Those increases were in directors fees (due to a full board of directors in 2018 versus vacancies in 2017), accounting fees (due to an increase in our fee schedule with our current auditor), bank service fees (as a result of the receipt of a waiver related to our non-compliance with the TNW covenant for our line of credit) and outside service fees (due to 2018 being a re-certification year for ISO).

Other income and expense:

Other expense in the six months ended June 30, 2018 consisted of interest expense associated with our credit facilities (our line of credit and equipment loan with Crestmark Bank and our two loans with Cherokee Financial, LLC), offset by other income related to gains on certain liabilities and a small amount of interest income. Other expense in the six months ended June 30, 2017 consisted of interest expense (related to our line of credit and equipment loan with Crestmark Bank and our loan and security agreement with Cherokee Financial, LLC) offset by other income related to gains on certain liabilities.

Results of operations for the three months ended June 30, 2018,

compared to the three months ended June 30, 2017

NET SALES: Net sales for the three months ended June 30, 2018 decreased $237,000, or 18.1%, when compared to the three months ended June 30, 2017. The majority of the sales decline is due to $236,000 in product sales to a government account lost in the latter part of the year ended December 31, 2017. The loss of this account is due to actions we have alleged were taken by a former Vice President Sales & Marketing/Sales Consultant (Todd Bailey) and, are the subject of ongoing litigation. There was an additional $19,000 in lost government product sales due to the expiration of a contract with another government entity. Contract manufacturing sales also contributed $14,000 to the sales loss with the anticipated expiration of one of our contract manufacturing agreements in early 2018). In the six months ended June 30, 2018, we did see some improvement in clinical markets and international sales, and we also saw increased sales of our lower cost product alternative. These improvements did minimally offset the declines.

GROSS PROFIT: Gross profit decreased to 40.9% of net sales in the three months ended June 30, 2018, from 43.3% of net sales in the three months ended June 30, 2017. This decrease in gross profit stems primarily from the fact that decreased sales resulted in a decrease in the number of testing strips made in the three months ended June 30, 2018 when compared to the three months ended June 30, 2017. The majority of our labor and overhead costs are fixed. When revenues decline, fewer testing strips are produced; this results in a manufacturing inefficiency (i.e. less fixed overhead cost absorption and a higher amount being expensed through cost of goods). In addition, the low product prices from foreign manufacturers have required us to decrease pricing of our own products to be more competitive. We have taken actions to adjust our production schedule to mitigate future inefficiencies.

Operating expenses decreased $92,000, or 15.7%, in the three months ended June 30, 2018 compared to the three months ended June 30, 2017. Expenses in all operational areas of the Company decreased. More specifically:

Research and development (“R&D”)

R&D expense decreased $3,000, or 13.6%, when comparing the three months ended June 30, 2018 with the three months ended June 30, 2017. Decreased FDA compliance costs (associated with the timing of actions taken related to our FDA marketing clearance application) were the primary reason for the decline in expenses along with decreased supplies expense. These declines in expense were partially offset by an increase in ~~supplies and materials. Our~~R&D salaries (due to the timing of a temporary leave by a R&D employee). In the six months ended June 30, 2018 our R&D department ~~continues to focus~~primarily focused their efforts on the ~~enhancement of current products, the~~evaluation and development of ~~new testing assays, new product platforms and the evaluation of~~potential contract manufacturing ~~opportunities.~~

opportunities as well as maintenance of our current product lines.

Selling and marketing

Selling and marketing expense in the ~~nine~~three months ended ~~September~~June 30, ~~2017~~2018 decreased ~~35.7%~~$28,000, or 15.9% when compared to the ~~same period last year. One~~three months ended June 30, 2017. Postage expense decreased along with marketing salaries and benefits (due to transitioning from an employee based approach to internet marketing to the use of ~~the primary reasons for the decline~~a consulting firm; this expense savings was only nominally offset by an increase in ~~expenses is decreased commission~~marketing consulting expense). These reductions were partially offset by freight expense. In the ~~latter~~three months ended June 30, 2018, we promoted additional products (through relationships with third parties) for the detection of alcohol, alternative sample options for drug testing (such as lab based oral fluid testing and hair testing) as well as toxicology management services and lower-cost alternatives for onsite drug testing. The addition of these offerings did not result in increased selling and marketing expenses. In the three months ended June 30, 2018, we refocused our efforts on further penetration of the clinical markets, took efforts to re-enter the workplace market with oral fluid drug testing options and increase our contract manufacturing business.

General and administrative (“G&A”)

G&A expense decreased $44,000, or 11.3%, in the three months ended June 30, 2018 when compared to G&A expense in the three months ended June 30, 2017. Decreases in SEC report fees (due to a change in vendor), QA salaries (due to retirement of an employee), QA supplies, broker fees (due to timing of financing activities), legal fees (due to timing of actions in the ABMC vs. Bailey et al litigation), patents and licenses (due to less patent activity) and share based a payment expense (due to less stock option amortization in 2018) were offset by certain increases. Those increases were in directors’ fees (due to a full board of directors in 2018 versus vacancies in 2017), accounting fees (due to an increase in our fee schedule with our current auditor), bank service fees (as a result of the receipt of a waiver related to our non-compliance with the TNW covenant for our line of credit) and transfer agent fees.

Other income and expense:

Other expense in the three months ended June 30, 2018 consisted of interest expense associated with our credit facilities (our line of credit and equipment loan with Crestmark Bank and our two loans with Cherokee Financial, LLC), offset by other income related to gains on certain liabilities and a small amount of interest income. Other expense in the three months ended June 30, 2017 consisted of interest expense (related to our line of credit and equipment loan with Crestmark Bank and our loan and security agreement with Cherokee Financial, LLC) offset by other income related to gains on certain liabilities.

Liquidity and Capital Resources as of June 30, 2018

Our cash requirements depend on numerous factors, including but not limited to manufacturing costs (such as raw materials, equipment, etc.), selling and marketing initiatives, product development activities, regulatory costs, legal costs associated with current litigation, and effective management of inventory levels and production levels in response to sales history and forecasts. We expect to devote capital resources related to selling and marketing initiatives and we expect that we will incur increased legal costs due to ongoing litigation in the year ending December 31, 2018. We are examining other growth opportunities including strategic alliances. Given our current and historical cash position, such activities would need to be funded from the issuance of additional equity or additional credit borrowings, subject to market and other conditions. Our financial statements for the year ended December 31, 2017 were prepared assuming we will continue as a going concern.

Our current cash balances, together with cash generated from future operations and amounts available under our credit facilities may not be sufficient to fund operations through August 2019. Our current line of credit expires on June 22, 2020 and has a maximum availability of $1,500,000. However, the amount available under our line of credit is based upon the balance of our accounts receivable and inventory so, we do not have the maximum available to borrow. As of June 30, 2018, based on our availability calculation, there were no additional amounts available under our line of credit because we draw any balance available on a daily basis. If sales levels continue to decline, we will have reduced availability on our line of credit due to decreased accounts receivable balances. In addition, we would expect our inventory levels to continue to decrease if sales levels decline further, which would result in further reduced availability on our line of credit. In addition to decreased inventory value, as a result of an amendment executed on June 25, 2018, the amount available under the inventory component of the line of credit was changed to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $250,000 (“Inventory Sub-Cap Limit”) or 100% of Eligible Accounts Receivable. In addition, the Inventory Sub-Cap Limit will be permanently reduced by $10,000 per month commencing on July 1, 2018 and on the first day of the month thereafter until the Inventory Sub-Cap Limit is reduced to $0. Although this “staggered” reduction will not have a material immediate impact on our availability under the line of credit, it will eventually result in no availability under the line of credit related to inventory and it will be an accounts receivable based line only.

If availability under our line of credit is not sufficient to satisfy our working capital and capital expenditure requirements, we will be required to obtain additional credit facilities or sell additional equity securities, or delay capital expenditures which could have a material adverse effect on our business. There is no assurance that such financing will be available or that we will be able to complete financing on satisfactory terms, if at all.

As of June 30, 2018, we had the following debt/credit facilities:

Facility	Debtor	Balance as of June 30, 2018
Loan and Security Agreement	Cherokee Financial, LLC	$975,000
Revolving Line of Credit	Crestmark Bank	$596,000
Equipment Loan	Crestmark Bank	$25,000
Term Loan	Cherokee Financial, LLC	$150,000
Total Debt		$1,746,000

Working Capital

Our working capital decreased $387,000 to $90,000 at June 30, 2018 from $477,000 at December 31, 2017. This decrease in working capital is primarily the result of decreased sales. We have historically satisfied working capital requirements through cash from operations and bank debt.

Dividends

We have never paid any dividends on our common shares and anticipate that all future earnings, if any, will be retained for use in our business, and therefore, we do not anticipate paying any cash dividends.

Cash Flow, Outlook/Risk

We have taken steps (and will continue to take steps) to ensure that operating expenses and manufacturing costs remain in line with sales levels, however, we are incurring increased costs related to litigation and other administrative requirements. In early 2018, we also took steps (and will incur additional sales and marketing expense) to further penetrate the rehabilitation/drug treatment, pain management and other clinical markets. To offset these investments, we consolidated job responsibilities in other areas of the Company and this enabled us to implement personnel reductions.

The decline in sales has resulted in lower than average cash balances and lower availability on our line of credit. Two large government accounts (one of which was in the year ended December 31, 2017 and the other in the year ended December 31, 2016) were lost due to alleged actions on the part of a former Vice President Sales and Marketing/Sales Consultant (Todd Bailey) and are the subject of ongoing litigation. These two accounts represented approximately $1,000,000 in annual sales to the Company (of which approximately $800,000 will impact sales revenues in the year ending December ~~2016, we terminated our relationship with a sales consultant due~~31, 2018 (when compared to ~~competitive issues that arose during our relationship; we subsequently filed a complaint against this consultant~~the year ended December 31, 2017). Also, in the early part of ~~2017 (See Note D – Litigation/Legal Matters). In addition~~2018, we had another government contract expire and this is also contributing to the sales decline in ~~commissions, sales salaries and benefits, customer relations expense, postage and marketing consulting expenses decreased. These~~the six months ended June 30, 2018 (when compared to the six months ended June 30, 2017). To address the declines, ~~were minimally offset by an increase in costs associated with trade show attendance. Our direct sales force continues to focus their efforts in our target markets, which include, but~~we are not limited to, Workplace, Government, and Clinical (i.e. pain management and drug treatment) and in the forensic and international markets for our oral fluid product. Our sales force has also started to promotepromoting new products and service offerings to diversify our revenue stream. These new products and services (through relationships with third parties) include products for the detection of alcohol, alternative sample options for drug testing (such as lab based oral fluid testing and hair testing) as well as toxicology management services and lower-cost alternatives for onsite drug testing. Also, a change in the regulatory environment (due to certain exemptions set forth by the U.S. Food and Drug Administration related to workplace and insurance drug testing) has resulted in new efforts to re-enter the workplace market with oral fluid drug testing options. And finally, we are currently discussing a number of contract manufacturing opportunities with ~~the FDA marketing clearance granted in August 2017, our sales force is also promoting the new market application of the product in the clinical market.~~

~~General and administrative (“G&A”)~~

G&A expense increased 4.3% in the nine months ended September 30, 2017 when compared to the same period last year. Increases in legal fees (due to the initiation of litigation in the early part of 2017; see Note D – Litigation/Legal Matters), and accounting fees were partially offset by reduced expenses related to investor relations (due to decreased travel), telephone and non-cash compensation (I.e. share based payment expense; due to less options outstanding subject to amortization). Share based payment expense was $33,000 in the nine months ended September 30, 2017 compared to $49,000 in the nine months ended September 30, 2016.

~~Results of operations for the three months ended September 30, 2017~~

~~compared to the three months ended September 30, 2016~~

~~NET SALES:~~Net sales for the three months ended September 30, 2017 declined 4.4% when compared to the three months ended September 30, 2016. The decrease in sales results from a decrease in government sales (mostother entities; one of which is ~~due~~expected to ~~the loss of an account~~generate sales starting in the ~~fourth~~3rd or 4th quarter of ~~2016), and a decline in contract manufacturing sales. These declines were partially offset by increased sales~~2018.

Our ability to ~~Latin America and South America and to national accounts.~~

~~GROSS PROFIT:~~Gross profit decreased to 41.8% of net sales in the three months ended September 30, 2017 compared to gross profit of 43.1% of net sales in the three months ended September 30, 2016. While we are still maintaining manufacturing efficiencies, there were certain periods within the three months ended September 30, 2017 that we produced less testing strips due to the product sales mix.

~~OPERATING EXPENSES:~~ Operating expenses decreased 16.4% in the three months ended September 30, 2017, compared to the three months ended September 30, 2016. Expenses in research and development and selling and marketing decreased while general and administrative expense increased. More specifically:

~~Research and development (“R&D”)~~

~~R&D expense decreased 7.1% when comparing the three months ended September 30, 2017~~remain compliant with the three months ended September 30, 2016. Decreased supplies and materials costs were partially offset by increased employee benefit costs. Our R&D department continues to focus their efforts on the enhancement ofour obligations under our current ~~products, the development of new testing assays, new product platforms and the evaluation of contract manufacturing opportunities.~~

~~Selling and marketing~~

Selling and marketing expense in the three months ended September 30, 2017 decreased 42.2% when compared to the three months ended September 30, 2016. One of the primary reasons for the decline in expenses is related to decreased commission expense. In the latter part of December 2016, we terminated our relationship with a sales consultant due to competitive issues that arose during our relationship; we subsequently filed a complaint against this consultant in the early part of 2017 (See Note D – Litigation/Legal Matters). In addition to the decline in commissions, sales salaries and benefits, customer relations expense, and marketing consulting expenses decreased. These declines were minimally offset by an increase sales travel expense. Our direct sales force continues to focus their efforts in our target markets, which include, but are not limited to, Workplace, Government, and Clinical (i.e. pain management and drug treatment) and in the forensic and international markets for our oral fluid product. Our sales force has also started to promote new products and service offerings to diversify our revenue stream. These new products and services (through relationships with third parties) include products for the detection of alcohol, alternative sample options for drug testing (such as lab based oral fluid testing and hair testing) as well as toxicology management services, and lower-cost alternatives for onsite drug testing. And finally, with the FDA marketing clearance granted in August 2017, our sales force is also promoting the new market application of the product in the clinical market.

~~General and administrative (“G&A”)~~

G&A expense increased 2.2% in the three months ended September 30, 2017 when compared to G&A expense in the three months ended September 30, 2016. Increased legal fees (due to the initiation of litigation in the early part of 2017; see Note D – Litigation/Legal Matters) were partially offset by reduced expenses related to telephone, consulting fees, brokers fees and non-cash compensation (i.e. share based payment expense; due to less options outstanding subject to amortization). Share based payment expense was $10,000 in the three months ended September 30, 2017 compared to $13,000 in the three months ended September 30, 2016.

~~Liquidity and Capital Resources as of September 30, 2017~~

~~Our cash requirements~~credit facilities will depend on ~~numerous factors, including but not limited~~our ability to ~~manufacturing costs (such as raw materials, equipment, etc.), selling~~replace lost sales and marketing initiatives, product development activities, regulatory costs, legal costs associated with current litigation, and effective management of inventory levels and production levels in response to sales forecasts. We expect to devote capital resources to continue selling and marketing initiatives and product development/research and development activities. We are examining other growth opportunities including strategic alliances. Given our current and historical cash position, we expect such activities would need to be funded from the issuance of additional equity or additional credit borrowings, subject to market and other conditions. Our financial statements for the year ended December 31, 2016 were prepared assuming we will continue as a going concern.

Our current cash balances, together with cash generated from future operations and amounts available under our credit facilities may not be sufficient to fund operations through November 2018. Our current line of credit expires on June 22, 2020 and has a maximum availability of $1,500,000. However, the amount available under our line of credit is based upon the balance of our accounts receivable and inventory. As of September 30, 2017, based on our availability calculation, there were no additional amounts available under our line of credit because we draw any balance available on a daily basis. If sales levels decline further we will have reduced availability on our line of credit due to decreased accounts receivable balances. In addition, we would expect our inventory levels to decrease if sales levels decline further, which would result in further reduced availability on our line of credit. If availability under our line of credit is not sufficient to satisfy our working capital and capital expenditure requirements, we will be required to obtain additional credit facilities or sell additional equity securities, or delay capital expenditures. There is no assurance that such financing will be available or that we will be able to complete financing on satisfactory terms, if at all.

~~As of September 30, 2017, we had the following debt/credit facilities:~~

Facility Debtor Balance as of September 30, 2017
Loan and Security Agreement Cherokee Financial, LLC $ 1,050,000
Revolving Line of Credit Crestmark Bank $ 580,000
Capital Equipment Loan Crestmark Bank $ 34,000

~~Working Capital~~

Our working capital was $664,000 at September 30, 2017; this is a decrease of $129,000 when compared to working capital of $793,000 at December 31, 2016. This decrease in working capital is primarily the result of decreasedincrease sales. ~~We have historically satisfied working capital requirements through cash from operations and debt.~~

~~Dividends~~

~~Cash Flow, Outlook/Risk~~

We do not expect significant increases in expenses during the year ending December 31, 2017 and as evidenced by our operating expenses for the year ended December 31, 2016 (“Fiscal 2016”), we have taken steps (and will continue to take steps) to ensure that operating expenses and manufacturing costs remain in line with sales levels. In 2017, we will continue to focus our efforts on improving sales. Such steps include, but are not limited to, further penetrating the Clinical markets such as pain management and drug treatment now that our Rapid TOX Cup II received OTC marketing clearance from FDA in August 2017 and entering into strategic relationships with third parties to offer additional products and services to our customers. This includes products for the detection of alcohol, alternative sample options for drug testing (such as lab based oral fluid testing and hair testing) as well as toxicology management services, and lower-cost alternatives for onsite drug testing. We are hopeful that these additional product and service offerings will have a positive impact on sales in the future. In the nine months ended September 30, 2017, we utilized cash resources to complete our FDA marketing application process (which resulted in a marketing clearance in August 2017) and to take other steps that could result in increased sales. In addition, cash resources have been utilized to initiate litigation against Premier Biotech Inc., and its President, Todd Bailey (a former Vice President and sales consultant of the Company), and Peckham Vocational Industries, Inc., among others. While we expect additional cash resources to be used related to the ligation, we do not expect additional expenditures related to marketing clearances in the year ending December 31, 2017.

None of these efforts related to sales, or any other efforts being taken related to other operational activities, resulted in a substantial increase in cash requirements in the nine months ended September 30, 2017. In the second quarter of the year ended December 31, 2016, we received our final payment of $150,000 related to a tech transfer with one of our contract-manufacturing customers. The loss of a state agency contract starting October 1, 2017 is expected to have a material impact on our sales. If we are unable to recoup this loss (which has historically been 10-15% of our annual sales), it is possible that our current line of credit (and advance rates) would not be adequate for our cash requirements in the year ending December 31, 2017, especially if expense levels do not decline in line with the sales decline and especially considering the costs related to litigation. In addition, extraordinary events could occur that would result in unexpected, increased expenditures.

If events and circumstances occur such that 1) we do not meet our current operating plans to increase sales, 2) we are unable to raise sufficient additional equity or debt financing, or 3) our credit facilities are insufficient or not available, we may be required to further reduce expenses or take other steps which could have a material adverse effect on our future performance.

Our ability to repay our current debt ~~will depend primarily upon our future operating performance, which~~ may also be affected by ~~the loss of a material contract in October 2017,~~ general economic, financial, competitive, regulatory, legal, business and other factors beyond our control, including those discussed herein. ~~In addition,~~If we ~~cannot assure you~~are unable to meet our credit facility obligations, we would be required to raise money through new equity and/or debt financing(s) and, there is no assurance that ~~future borrowings~~we would be able to find new financing, or ~~equity~~that any new financing ~~will~~would be ~~available~~at favorable terms.

We were not in compliance with the TNW covenant under our Crestmark LOC as of June 30, 2018; however, we received a waiver from Crestmark for the ~~payment of any indebtedness we may have.~~

~~Our~~quarter ended June 30, 2018. A failure to comply with the TNW covenant under our ~~revolving credit facility~~Crestmark LOC (a failure that is not waived by Crestmark) could result in an event of default, which, if not cured, ~~or waived,~~ could result in the Company being required to pay much higher costs associated with the indebtedness. This results in the Equipment Loan being due and payable if called by Crestmark, however, Crestmark has not taken this action as of the date of this report. If we are forced to refinance our debt on less favorable terms, our results of operations and financial condition could be adversely affected by increased costs and rates. We may also be forced to pursue one or more alternative strategies, such as restructuring, selling assets, reducing or delaying capital expenditures or seeking additional equity capital. There can be no assurances that any of these strategies could be implemented on satisfactory terms, if at all.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this item.

Item 4. Controls and Procedures

~~(a)~~

~~Evaluation of Disclosure Controls and Procedures~~

(a) Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer (Principal Executive Officer)/Chief Financial Officer (Principal Financial Officer), together with other members of management, has reviewed and evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 Rule 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based on this review and evaluation, our Principal Executive Officer/Principal Financial Officer concluded that our disclosure controls and procedures are effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported in a timely manner.

~~(b)~~

~~Changes in Internal Control Over Financial Reporting~~

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the last quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See Part I, Item 1, Note D in the Notes to ~~the~~ interim condensed Financial Statements included in this report for a description of pending legal proceedings in which we may be a party.

Item 1A. Risk Factors

Inability to comply with financial covenants under our current line of credit facility and an inability to comply with our debt obligations could result in our creditors declaring all amounts owed to them due and payable with immediate effect, or result in the collection of collateral by the creditor; both of which would have an adverse material impact on our business and our ability to continue operations.

We have a credit facility with Crestmark Bank consisting of revolving line of credit (the “Crestmark LOC”). The Crestmark LOC is secured by a first security interest in all of our receivables and inventory and security interest in all other assets of the Company (in accordance with permitted prior encumbrances), (together the “Collateral”). So long as any obligations are due to Crestmark, the Company must comply with a minimum Tangible Net Worth (“TNW”) Covenant. As a result of an amendment executed on June 25, 2018, the TNW covenant was reduced from $650,000 to $150,000 as of June 30, 2018. Additionally, if a quarterly net income is reported, the TNW covenant will increase by 50% of the reported net income. If a quarterly net loss is reported, the TNW covenant will remain the same as the prior quarter’s covenant amount. TNW is still defined as: Total Assets less Total Liabilities less the sum of (i) the aggregate amount of non-trade accounts receivables, including accounts receivables from affiliated or related persons, (ii) prepaid expenses, (iii) deposits, (iv) net lease hold improvements, (v) goodwill and (vi) any other asset that would be treated as an intangible asset under GAAP; plus Subordinated Debt. Subordinated Debt means any and all indebtedness presently or in the future incurred by the Company to any creditor of the Company entering into a written subordination agreement with Crestmark. The Company has not complied with the TNW covenant since the year ended December 31, 2017 and, most recently has not complied with the TNW covenant for June 30, 2018. Previously (and including as of June 30, 2018) the Company received a waiver from Crestmark.

In addition to the Crestmark LOC, we have a loan and security agreement with Cherokee Financial, LLC., which is secured by a first security interest in our real estate and machinery and equipment. In addition to general economic, financial, competitive, regulatory, business and other factors beyond our control, our ability to make payments to Cherokee Financial, LLC will depend primarily upon our future operating performance, which, to date, has been affected by the loss of a material contract in Fiscal 2017. In February 2018, we entered into a new loan facility with Cherokee Financial, LLC to pay a $75,000 principal reduction payment due to them.

A failure to comply with the Crestmark LOC TNW covenant (that is not waived by Crestmark Bank) and/or repay any of our debt obligations could result in an event of default, which, if not cured or waived, could result in the Company being required to pay much higher costs associated with the indebtedness and/or enable our creditors to declare all amounts owed to them due and payable with immediate effect. If we are forced to refinance our debt on less favorable terms, our results of operations and financial condition could be adversely affected by increased costs and rates. We may also be forced to pursue one or more alternative strategies, such as restructuring, selling assets, reducing or delaying capital expenditures or seeking additional equity capital. There can be no assurances that any of these strategies could be implemented on satisfactory terms, if at all, or that future borrowings or equity financing would be available for the payment of any indebtedness we may have. In addition, in an event of default, our creditors could begin proceedings to collect the collateral securing the debt. This would have a material adverse effect on the Company’s ability to continue operations.

Apart from the risk factor set forth above, there have been no material changes to our risk factors set forth in Part I, Item 1A, in our Annual Report on Form 10-K for the year ended December 31, ~~2016, except for those disclosures made in our Form 10-Q for the three and six months ended June 30, 2017 filed with the Commission on August 14,~~ 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~None.~~

As previously disclosed in a Section 16(a) filing made by our Chairman of the Board Chaim Davis with the U.S. Securities and Exchange Commission on June 27, 2018 and, in accordance with our director compensation structure approved by the Company’s Board of Directors on March 22, 2018 (as indicated in the Company’s Proxy Statement filed on April 20, 2018), Mr. Davis was issued 33,784 shares of restricted common stock in lieu of cash for his attendance at a Board of Directors meeting held in June 2018.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

	~~31.1/31.2~~	~~Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer/Chief Financial Officer~~

	~~32.1/32.2~~	~~Certification of the Chief Executive Officer/Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002~~

	~~101~~	The following materials from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Balance Sheet, (ii) Condensed Statements of Income (iii) Condensed Statements of Cash Flows, and (iv) Notes to Condensed Financial Statements.

31.1/31.2

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer/Chief Financial Officer

32.1/32.2

Certification of the Chief Executive Officer/Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101

The following materials from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Balance Sheet, (ii) Condensed Statements of Income (iii) Condensed Statements of Cash Flows, and (iv) Notes to Condensed Financial Statements.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMERICAN BIO MEDICA CORPORATION
	(Registrant)

Dated: August 14, 2018	By:	/s/ Melissa A. Waterhouse
		Melissa A. Waterhouse
		Chief Executive Officer (Principal Executive Officer)
	Principal Financial Officer
	Principal Accounting Officer

~~Dated: November 14, 2017~~

		~~PAGE~~
PART I – FINANCIAL INFORMATION		PAGE

Item 1.	Condensed Financial Statements	3

~~Item 1.~~	~~Condensed Financial Statements~~	3
	Condensed Balance Sheets as of ~~September~~June 30, ~~2017~~2018 (unaudited) and December 31, ~~2016~~2017	3
	Condensed Unaudited Statements of Operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~September~~June 30, ~~2016~~2017	4
	Condensed Unaudited Statements of Cash Flows for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~September~~June 30, ~~2016~~2017	6
	Notes to Condensed Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15 16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20 22
Item 4.	Controls and Procedures	20 22

	September 30,			December 31,
	2017			2016
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	150,000		$	156,000
Accounts receivable, net of allowance for doubtful accounts of $51,000 at September 30, 2017 and $49,000 at December 31, 2016		521,000			556,000
Inventory, net of allowance of $453,000 at September 30, 2017 and $449,000 at December 31, 2016		1,462,000			1,582,000
Prepaid expenses and other current assets		49,000			92,000
Total current assets		2,182,000			2,386,000

Property, plant and equipment, net		810,000			824,000
Patents, net		107,000			93,000
Other assets		21,000			21,000
Deferred finance costs – line of credit, net		23,000			47,000
Total assets	$	3,143,000		$	3,371,000

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	306,000		$	304,000
Accrued expenses and other current liabilities		287,000			276,000
Wages payable		257,000			299,000
Line of credit		580,000			639,000
Current portion of long-term debt		87,000			75,000
Total current liabilities		1,517,000			1,593,000

Long-term debt, net of current portion and deferred finance costs		748,000			753,000
Other long-term liabilities		22,000			0
Total liabilities		2,287,000			2,346,000

COMMITMENTS AND CONTINGENCIES

Stockholders’ equity:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at September 30, 2017 and December 31, 2016		0			0
Common stock; par value $.01 per share; 50,000,000 shares authorized; 29,297,333 issued and outstanding at September 30, 2017 and 28,842,788 issued and outstanding at December 31, 2016		293,000			288,000
Additional paid-in capital		21,115,000			21,037,000
Accumulated deficit		(20,552,000	)		(20,300,000	)
Total stockholders’ equity		856,000			1,025,000
Total liabilities and stockholders’ equity	$	3,143,000		$	3,371,000

American Bio Medica Corporation
Condensed Balance Sheets
	June 30,	December 31,
	2018	2017
ASSETS	(Unaudited)
Current assets
Cash and cash equivalents	$76,000	$36,000
Accounts receivable, net of allowance for doubtful accounts of $56,000 at June 30, 2018 and $52,000 at December 31, 2017	512,000	348,000
Inventory, net of allowance of $541,000 at June 30, 2018 and $500,000 at December 31, 2017	1,261,000	1,473,000
Prepaid expenses and other current assets	33,000	97,000
Total current assets	1,882,000	1,954,000

Property, plant and equipment, net	754,000	792,000
Patents, net	119,000	109,000
Other assets	21,000	21,000
Deferred finance costs – line of credit, net	0	15,000
Total assets	$2,776,000	$2,891,000

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$349,000	$374,000
Accrued expenses and other current liabilities	358,000	311,000
Wages payable	252,000	259,000
Line of credit	596,000	446,000
Current portion of long-term debt	237,000	87,000
Total current liabilities	1,792,000	1,477,000

Other liabilities/debt	13,000	19,000
Long-term debt, net of current portion and deferred finance costs	733,000	772,000
Total liabilities	2,538,000	2,268,000

COMMITMENTS AND CONTINGENCIES

Stockholders' equity:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at June 30, 2018 and December 31, 2017	0	0
Common stock; par value $.01 per share; 50,000,000 shares authorized; 29,966,554 issued and outstanding at June 30, 2018 and 29,782,770 issued and outstanding as of December 31, 2017	300,000	298,000
Additional paid-in capital	21,196,000	21,170,000
Accumulated deficit	(21,258,000)	(20,845,000)
Total stockholders’ equity	238,000	623,000
Total liabilities and stockholders’ equity	$2,776,000	$2,891,000

	For The Nine Months Ended
	September 30,
	2017			2016

Net sales	$	3,975,000		$	4,392,000

Cost of goods sold		2,279,000			2,441,000

Gross profit		1,696,000			1,951,000

Operating expenses:
Research and development		94,000			136,000
Selling and marketing		531,000			827,000
General and administrative		1,154,000			1,106,000
		1,779,000			2,069,000

Operating loss		(83,000	)		(118,000	)

Other income / (expense):
Interest expense		(204,000	)		(210,000	)
Other income, net		34,000			200,000
		(170,000	)		(10,000	)

Net loss before tax		(253,000	)		(128,000	)

Income tax benefit / (expense)		1,000			(2,000	)

Net loss	$	(252,000	)	$	(130,000	)

Basic and diluted loss per common share	$	(0.01	)	$	(0.01	)

Weighted average number of shares outstanding – basic & diluted		29,129,168			27,056,216

American Bio Medica Corporation
Condensed Statements of Operations
(Unaudited)
	For The Six Months Ended
	June 30,
	2018	2017
Net sales	$2,110,000	$2,621,000

Cost of goods sold	1,301,000	1,491,000

Gross profit	809,000	1,130,000

Operating expenses:
Research and development	44,000	68,000
Selling and marketing	310,000	372,000
General and administrative	736,000	778,000
	1,090,000	1,218,000

Operating loss	(281,000)	(88,000)

Other income / (expense):
Interest expense	(146,000)	(134,000)
Other income, net	15,000	20,000
Interest income	1,000	0
	(130,000)	(114,000)

Net loss before tax	(411,000)	(202,000)

Income tax expense	(2,000)	(1,000)

Net loss	$(413,000)	$(203,000)

Basic and diluted loss per common share	$(0.01)	$(0.01)

Weighted average number of shares outstanding – basic & diluted	29,879,754	29,043,692

	For The Three Months Ended
	September 30,
	2017			2016

Net sales	$	1,354,000		$	1,417,000

Cost of goods sold		788,000			806,000

Gross profit		566,000			611,000

Operating expenses:
Research and development		26,000			28,000
Selling and marketing		159,000			275,000
General and administrative		376,000			368,000
		561,000			671,000

Operating income / (loss)		5,000			(60,000	)

Other income / (expense):
Interest expense		(70,000	)		(71,000	)
Other income, net		14,000			44,000
		(56,000	)		(27,000	)

Net loss before tax		(51,000	)		(87,000	)

Income tax benefit / (expense)		2,000			(1,000	)

Net loss	$	(49,000	)	$	(88,000	)

Basic and diluted loss per common share	$	(0.00	)	$	(0.00	)

Weighted average number of shares outstanding – basic & diluted		29,297,333			27,284,308

American Bio Medica Corporation
Condensed Statements of Cash Flows
(Unaudited)
	For The Six Months Ended
	June 30
	2018	2017
Cash flows from operating activities:
Net loss	$(413,000)	$(203,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	42,000	43,000
Amortization of debt issuance costs	70,000	63,000
Allowance for doubtful accounts	4,000	0
Provision for slow moving and obsolete inventory	41,000	19,000
Share-based payment expense	7,000	23,000
Changes in:
Accounts receivable	(168,000)	74,000
Inventory	171,000	113,000
Prepaid expenses and other current assets	64,000	54,000
Accounts payable	(25,000)	(26,000)
Accrued expenses and other current liabilities	48,000	(13,000)
Wages payable	(7,000)	(31,000)
Net cash (used in) / provided by operating activities	(166,000)	116,000

Cash flows from investing activities:
Patent application costs	(13,000)	(13,000)
Purchase of property, plant and equipment	0	(38,000)
Net cash used in investing activities	(13,000)	(51,000)

Cash flows from financing activities:
Proceeds from / (payments on) debt financing	69,000	(38,000)
Proceeds from lines of credit	2,235,000	2,835,000
Payments on lines of credit	(2,085,000)	(2,880,000)
Net cash provided by / (used in) financing activities	219,000	(83,000)

Net change in cash and cash equivalents	40,000	(18,000)
Cash and cash equivalents - beginning of period	36,000	156,000

Cash and cash equivalents - end of period	$76,000	$138,000

Supplemental disclosures of cash flow information
Non-cash transactions:
Consulting expense prepaid with restricted stock	$42,000	$50,000
Debt issuance cost paid with restricted stock	$18,000	$0
Director Fee paid with restricted stock	$3,000	$0
Cash paid during period for interest	$76,000	$71,000
Cash paid during period for taxes	$2,000	$1,000

	September 30, 2017			December 31, 2016

Raw Materials	$	1,053,000		$	1,028,000
Work In Process		438,000			385,000
Finished Goods		424,000			618,000
Allowance for slow moving and obsolete inventory		(453,000	)		(449,000	)
	$	1,462,000		$	1,582,000

	September 30, 2017		September 30, 2016

Warrants		2,060,000		2,060,000
Options		2,147,000		2,182,000
		4,207,000		4,242,000

	June 30, 2018	December 31, 2017
Loan and Security Agreement with Cherokee Financial, LLC: 5 year note at an annual interest rate of 8% plus a 1% annual oversight fee, interest only and oversight fee paid quarterly with first payment being made on May 15, 2015, annual principal reduction payment of $75,000 due each year beginning on February 15, 2016, with a final balloon payment being due on February 15, 2020. Loan is collateralized by a first security interest in building, land and property.	$975,000	$1,050,000
Crestmark Line of Credit: 3 year line of credit maturing on June 22, 2020 with interest payable at a variable rate based on WSJ Prime plus 3% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 2% if terminated prior to natural expiration. Loan is collateralized by first security interest in receivables and inventory and the all-in interest rate as of the date of this report is 13.1%.	596,000	446,000
Crestmark Equipment Loan: 38 month equipment loan related to the purchase of manufacturing equipment, at an interest rate of WSJ Prime Rate plus 3%; or 8.00% as of the date of this report.	25,000	31,000
Term Loan with Cherokee Financial LLC: 1 year note at an annual interest rate of 12% paid quarterly in arrears with first interest payment being made on May 15, 2018 and a balloon payment being due on February 15, 2019.	150,000	0
	1,746,000	1,527,000
Less debt discount & issuance costs (Cherokee Financial LLC loans)	(167,000)	(203,000)
Total debt, net	1,579,000	1,324,000

Current portion	833,000	533,000
Long-term portion, net of current portion	$746,000	$791,000

	Nine months ended September 30, 2017						Nine months ended September 30, 2016
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value as of September 30, 2017		Shares			Weighted Average Exercise Price		Aggregate Intrinsic Value as of September 30, 2016
Options outstanding at beginning of period		2,107,000	$	0.13				1,435,000		$	0.13
Granted		40,000	$	0.13				830,000		$	0.11
Exercised		0		NA				0			NA
Cancelled/expired		0		NA				(83,000	)	$	0.19
Options outstanding at end of period		2,147,000	$	0.13	$	15,000		2,182,000			0.13	$	30,000
Options exercisable at end of period		1,647,000	$	0.13				1,184,000		$	0.14

	Nine months ended
	2017			2016
Volatility		81	%		62% - 66	%
Expected term (years)		10 years			10 years
Risk-free interest rate		2.16	%		1.57% - 1.94	%
Dividend yield		0	%		0	%

Facility	Debtor	Balance as of September 30, 2017
Loan and Security Agreement	Cherokee Financial, LLC	$	1,050,000
Revolving Line of Credit	Crestmark Bank	$	580,000
Capital Equipment Loan	Crestmark Bank	$	34,000